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Interrogating disease with human lung optical imaging could improve the outcomes of 
clinical trials, provide early validation of lead candidates within drug discovery 
programmes, whilst also offering diagnostic capabilities. Optical molecular imaging 
using smart fluorescent probes (SmartProbes) provides a safe and affordable technique 
to analyse multiple lung pathologies and diseases, such as fibrosis and chronic 
obstructive pulmonary disease (COPD). The aim of this project was to develop 
families of SmartProbes and validate their biological utility.  
 
Macrophages are a key inflammatory cell in the lung. The ability to image these cells 
gives an understanding of macrophage biology, along with their interactions with other 
host-cells in the lung. SmartProbes were targeted to macrophages via receptors that 
they express highly, notably the folate receptor and macrophage mannose receptor. 
The synthesis of SmartProbes targeting these markers and their biological evaluation, 
is reported. 
 
Epithelial cells line the surface of the lung and can become damaged during a number 
of lung diseases. Certain diseases involve a process known as senescence, this is a 
process of cellular aging and its role is to indicate the need for repair. To visualise 
these processes, activity-based SmartProbes that can sensitively detect esterases and 
beta-galactosidase were synthesised. Esterase probes were evaluated in enzyme and 






The prospect of an optical biopsy to interrogate disease within the human lung offers 
the ability to improve the outcomes of clinical trials, provide early validation within 
drug discovery programmes, while also offering diagnostic capabilities. Optical 
molecular imaging using smart fluorescent probes offers a safe and affordable 
technique to allow the analysis of multiple lung pathologies and diseases such as 
fibrosis and chronic obstructive pulmonary disease (COPD). The aim of this project 
was to develop a number of families of SmartProbes and validate their biological 
utility.  
 
Macrophages are a valuable imaging target due to their key role in maintaining 
homeostasis and responding to inflammatory stimuli in the lung. Imaging these cells 
will allow us to dynamically observe macrophage biology and the multitude of host 
cell interactions within the lung. SmartProbes were targeted to macrophages via the 
cell specific markers - the macrophage mannose and folate receptors. The synthesis of 
SmartProbes targeting the folate receptor, including the application of new solid phase 
methodology to simplify the synthesis of these probes, is reported. In vitro studies 
were carried out in cancer cells and primary human monocyte-derived macrophages. 
An anti-MMR nanobody that targets the mannose receptor was fluorescently labelled 
to give a near-infrared SmartProbe. Its specificity and selectivity was assessed with 
primary immune cells and ex vivo clinical lung samples. 
 
The epithelial barrier is a layer of cells that line the lung and undergoes remodelling 
during diseases such as COPD and idiopathic pulmonary fibrosis (IPF). Hence, 
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methods to visualise epithelial integrity were sought. SmartProbes that were pro-
fluorophores for beta-galactosidase were synthesised. Beta-galactosidase probes were 
applied in epithelial cell models and murine tissue, allowing the detection of 
senescence associated beta-galactosidase (SA-βGal) positive senescent cells in 3D 
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1. Molecular imaging in the lung 
Medical imaging techniques such as magnetic resonance imaging (MRI) and X-ray 
computed tomography (CT) are widely used within healthcare systems, along with the 
nuclear imaging techniques of positron emission tomography (PET) and single-photon 
emission computed tomography (SPECT).2 These imaging techniques provide 
predominately structural information about a patient, however they have limitations 
such as cost and the use of radioactive materials (PET and SPECT). Thus, the 
development of new imaging techniques that are safer, cheaper and offer molecular 
information would be beneficial for the diagnosis of disease. One such modality, 
optical molecular imaging, is capable of giving cellular level resolution images, 
allowing the interrogation of biological events at a molecular level.3 
 
At this point it is worth considering the specific definition of molecular imaging since 
it is the focus of this thesis. It is defined as “the visualisation of in vivo biological 
processes at a molecular level using optical probes”.4 Molecular imaging has a wide 
scope of biomedical applications and has already been applied in cardiology and 
oncology, and inflammatory diseases.5-7 For example, fluorescein is used in 
ophthalmology for assessing the vascular structure of the eye,8 while indocyanine 
green (ICG) is used as a tracer of liver function and vasculature in the eye, heart and 






1.1. Optical imaging 
Optical molecular imaging relies on the emission of light in the form of fluorescence 
and is a high resolution method to generate molecular level of information. Absorption 
of light by a fluorophore gives a singlet excited state (S1) which can relax through 
several pathways including fluorescence (S1→ S0 + hν), phosphorescence (S1→ T1 → 
S0) and non-radiative decay. This can be described by a Jablonski diagram (Figure 
1.1). The absorption maxima and emission maxima are characteristic of each 
fluorophore.  
 
Figure 1.1. A Jablonski diagram showing the ground (S0), first (S1), and second (S2) 
excited electronic states and the transitions between states as vertical lines. Internal 
conversion involves rapid relaxation of higher vibrational states to S1 in ~10
−12 s. 
Return to the ground state results in fluorescence emission, or alternatively conversion 
to the T1 state followed by emission as phosphorescence. Reprinted by permission 
from Springer Nature: Principles of Fluorescence Spectroscopy (J.R. Lakowicz), 
copyright (2006).10 
 
Optical molecular imaging technology is available at a much lower cost than other 
imaging techniques such as PET that requires sophisticated imaging equipment and 
on-site radioisotope production due to their short half-lives. Unlike PET, optical 




guided surgery is becoming possible for tumour resection.13 Complete tumour removal 
is difficult with conventional microscopy as visually determining tumour-free margin 
is problematic. With fluorescence guided surgery, surgeons were able to assess the 
extent of excision in real-time using a fluorescent label that ‘lights up’ the tumour (see 
Figure 1.3).  
 
Figure 1.3. A demonstration of the power of molecular imaging for the detection of 
lung adenocarcinomas using the FITC-folate probe. A patient was diagnosed with lung 
adenocarcinoma by CT, PET and optical molecular imaging using the Artemis 
Fluorescence Imaging System. Intraoperative imaging provides clear identification of 
cancer cells stained with a fluorescent agent. Reprinted from Okusanya et al.14, 
Copyright (2015), with permission from Elsevier. 
 
Optical endomicroscopy via an optical fibre imaging bundle can give microscopic 
analysis and has the capability to explore a variety of cavities. More recently, imaging 
fibre endomicroscopy has been used in the lung for the in vivo detection of bacteria,15 
as well as in the GI tract to show changes due to colorectal polyps.16  There are a 
number of optical endomicroscopy platforms from clinical to developmental systems 
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(as demonstrated in Figure 1.4),1, 15 although standardisation is a key challenge to 
producing useful diagnostic information.17 
 
Figure 1.4. An example of optical endomicroscopy of multiple targets in ex vivo lung 
tissue including (a) monocytes, (b) neutrophils, and (c) fungus (Aspergillus fumigatus) 
by a Proteus system. Copyright Krstajić et al.15 Reproduced under a Creative 
Commons Attribution 3.0 Unported License.  
 
The Proteus team in Edinburgh has a current focus on improving molecular imaging 
technologies in the human lung. These new technologies have the power to impact the 
drug discovery progress by enriching assay outputs, accelerating development and 
enabling better drug response metrics in clinical trials. 
 
1.3. Design of Smartprobes 
A recent focus in the field of optical imaging are so-called “Smartprobes”, agents that 
should only fluoresce after activation and engagement with a target.18 These 
fluorescent molecules have been tuned to give a variety of different properties and to 
allow visualisation of targets of interest. A plethora of Smartprobes have been 
designed that target disease relevant targets, such as c-Met expression19, proteases20, 
receptor expression, glutathione21, hypochlorous acid22 and reactive oxygen species.23 
An in depth review of peptide optical probes for the clinical imaging of specific targets 
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in the areas of cancer, inflammation and infection was carried out by Staderini in 
2018.24 
 
1.3.1. NIR dyes 
The existing toolbox of fluorescent dyes is vast but focused on a number of “core” 
fluorophore scaffolds; these typically cover emission wavelengths from 300 to 900 
nm, a range of photophysical properties and chemical functionalities.25 However, 
common problems with fluorophores in a medical imaging setting is their poor 
aqueous solubility or high levels of aggregation, while existing Food and Drug 
Administration (FDA) approved NIR fluorophores are limited (Figure 1.5).  Synthetic 
chemistry can be used to modulate the fluorescent properties of fluorophores towards 
the ideal properties of; emission towards the red or infrared region (600-900 nm), 




Figure 1.5. Near-infrared dyes or precursors currently used in clinical applications. 5-
aminolevulinic acid (5-ALA) via biosynthesis of the fluorescent protoporphyrin XI 




One suitable class of NIR dyes having most desired properties are the cyanines. Their 
naming is based on the number of carbons in the polymethine chain, n = 3, 5, 7, being 




Figure 1.6. The structure of cyanine dyes comprises two heterocyclic groups 
connected by a methine chain, usually with an odd number of carbons. Varying the 
structure from n = 3, 5 or 7 methines changes their emission properties from the visible 
to the near infrared, allowing the molecule to be tuned to the desired wavelength. The 
backbone of cyanine dyes allows delocalisation of electrons along the polymethine 
chain to give their fluorescent properties. 
 
A clear limitation of commercially available NIR dyes is their propensity for 
nonspecific binding, uptake and retention, due to their hydrophobicity.27 To some 
extent, it is necessary to optimise the choice of fluorophore as this can have a 
significant effect on a probes biodistribution.27 The highly sulfonated Cy5** dye was 
previously developed by GE Healthcare to avoid these problems (Figure 1.7). This 
dye is known to have high water solubility and fast renal clearance.19 Due to the penta-
sulfonated nature of the dye, it would be advantageous over existing commercial Cy5 







1.3.3.2. Photoinduced electron transfer  
In a photoinduced electron transfer (PeT) system excitation of a fluorophore (donor) 
permits electron transfer from the acceptor partner, rather than electronic relaxation 
that leads to fluorescence. This occurs provided the oxidation potential of the acceptor 
is smaller than the donor and the PeT process results in quenching. In the presence of 
an analyte that changes the oxidation potential of the acceptor group, PeT becomes 
energetically unfavourable resulting in dequenching.31  
 
A related mechanism is intramolecular charge transfer (ICT) which can occur in a 
molecule with both donor and acceptor moieties. In an excited state, electron transfer 
occurs from one part of the molecule to another.10 This has been exploited in molecules 
by masking the electron donating group with a chemical moiety to change the 
fluorescent emission.  
 
1.4. Macrophages 
Macrophages (from the Greek: big eater) are an immune cell. Along with other 
leukocytes, macrophages are found throughout the body and play a key role in both 
the initiation and resolution of inflammation. Their roles include phagocytosis of 
debris and foreign material, signalling and activation of the immune system through 
cytokine and chemokine release. Defects in macrophage function can also lead to 
certain pathologies.32 A major area of biomedical research is furthering the 




Macrophage functions are known to be specialised to tissues in which they reside. In 
the lung, alveolar macrophages are adapted to the challenging environment they face; 
varying oxygen concentrations, contact with toxic inhaled particles and environmental 
antigens.32 Alveolar macrophages are long lived and approximately 40% are replaced 
in a year. Compared to airway macrophages, alveolar macrophages show decreased 
phagocytic ability until activated and they produce specific cytokines.32 
 
Macrophages are differentiated from monocytes and this process is regulated by a 
number of growth factors (Figure 1.10).33 To study macrophage biology, different 
models have been used. Peritoneal or bone marrow derived macrophages can be 
isolated from mice, however there are limitations in comparing mice and human cells, 
since features of the immune system are species specific.34 Human macrophage cell 
lines can also be used such as U937 and THP-1, however these are derived from 
cancerous tissues. An alternative method is to isolate peripheral blood mononuclear 
cells (PBMCs) from whole blood. After the lysis of red blood cells, a monocyte 
population can be purified from other immune cells by cell separation with 
magnetically tagged antibodies.35, 36 Subsequently these cells can be stimulated in vitro 





Figure 1.10. Mononuclear phagocyte lineage. Monocytes develop in bone marrow 
from pluripotent stem cells. Subpopulations of monocytes (including Ly6Chi and 
Ly6Clow) develop depending on the stimuli shown in yellow boxes. Alternatively 
activated macrophage differentiate through interleukin-13 (IL-13) and IL-4; 
inflammatory macrophages develop under the influence of GM-CSF, interferon-γ 
(IFN-γ) and tumour necrosis factor (TNF); Angiopoietin-1 receptor (TIE2)-expressing 
monocytes (TEMs) give rise to TIE2+ macrophages. The rigid lineage diagrams and 
growth factor assignments depicted here are for illustrative purposes only. Adapted by 
permission Springer Nature: Nature Reviews Immunology, Pollard.33 Copyright 2009 
Nature Publishing Group. 
 
1.4.1. Macrophage activation 
Macrophages respond to different signals triggering activation. This results in a change 
in cell phenotype which have been broadly classified as M1 and M2 states. M1 
macrophages have commonly been referred to as ‘classically activated’ or ‘pro-
inflammatory’, with the M2 phenotype as ‘alternatively activated’ or ‘anti-
inflammatory’ (Figure 1.11). Although it is now understood that macrophages do not 
always fit into these strict classifications and have ‘plasticity’ - the ability to move 





There is a practical need to develop new chemical probes to aid the diagnosis of 
chronic conditions affecting the lung. This thesis aims to address this through the 
synthesis of novel Smartprobes targeting processes relevant to pulmonary 
inflammation and validating their use in biological studies, with the aim to progress 
these for clinical use. Three sets of probes were investigated in this project. 
 
In order to visualise alveolar macrophages, Smartprobes were synthesised to target 
macrophages via cell-surface receptors. The folate receptor was targeted using folic 
acid-fluorophore conjugates and their use validated by in vitro studies with cancer cells 
and human macrophages. The macrophage mannose receptor (MMR) was targeted 
with an MMR specific nanobody that was fluorescently labelled to give a near-infrared 
probe for identifying macrophages and was tested with primary macrophages.  
 
To track the damage caused to the epithelial barrier by acute lung conditions, 
biomarkers of epithelial cell damage were investigated. Near-infrared beta-
galactosidase probes were evaluated to detect senescent cells that expressed 
senescence-associated beta-galactosidase (SA-βGal). These activatable probes were 
validated in vitro and murine tissue slices.  
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2. Folate receptor probes 
Folic acid is an essential nutrient classified as vitamin B9 and was discovered in 1941 
by Esmond Snell. Snell first isolated the compound from spinach and named it after 
the Latin for ‘leaf’, folium. Metabolism of folic acid provides multiple forms that 
participate in the one carbon metabolism pathway. These folates are key for the 
biochemical conversion of homocysteine into methionine, deoxyuridylate (dUMP) to 
thymidylate (dTMP) and de novo purine biosynthesis. Folic acid thus plays a crucial 
role in DNA synthesis and it is an essential nutrient in a human diet since it cannot be 
synthesised in the body. Interfering with the folate metabolic pathway has been a 
druggable target for several decades, especially as antimicrobials and in cancers where 
folate is needed to support cell growth. This led to the development of a number of 
licensed drugs (often called antifolates), among those is the chemotherapy drug 
methotrexate which inhibits dihydrofolate reductase (DHFR).39 
 
2.1. Folate receptors 
The folate receptor gene family has four isoforms FR-α, FR-β, FR-γ and FR-δ. The 
most studied are FR-α which is expressed in epithelial tissues and FR-β which is 
restricted to myeloid lineage cells; both isoforms are glycosylphosphatidylinositol 
(GPI) anchored receptors. The restricted expression of FR-α and FR-β to these tissues 
makes folate imaging conjugates useful for their visualisation in cancers and 




Over the years a number of different folate targeting imaging agents have been 
developed, taking advantage of the high affinity of folate derivatives for their receptor 
targets.41-46 However, many have not been translated further. Recently, a 
demonstration of the capabilities of folate targeting during fluorescence guided 
surgery of cancer was described by Mahalingam et al.47 OTL38 is an NIR labelled 
folate which accumulates in cancer tissue, has a high target affinity and enables the 
visualisation of cancer tissue using image-guided surgery (Figure 2.1 and see Figure 
2.2 for the structure of OTL38). This agent allows the surgeon to see tumour nodules 
to help improve surgical resection. OTL38 has completed Phase I and II clinical trials 
for ovarian and lung cancers and is now in Phase III trials for the detection of FR+ 
ovarian cancer (NCT03180307). 
 
 
Figure 2.1. Clinical uses of OTL38 showing A) Preoperative CT image of pulmonary 
tumor nodal, B) overlay of fluorescence image over white light image of pulmonary 
tumor nodal, and C) immunohistochemical (IHC) staining of resected pulmonary 
tumor nodal indicating tumor is FRα+. Representative fluorescence images over white 
light images of primary and metastatic ovarian tumors in D) uterine adnexa and E) 
uterus and bladder peritoneum. Note: LT = lung tumor, HL = healthy lung, FSF = 
Foerster sponge forceps, SF = surgeons fingers, and C = cotton. Adapted with 




A B C D E 
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2.1.1. Folate conjugates for molecular imaging 
The previous studies demonstrate that conjugates of folic acid are applicable for the 
imaging of FR+ cells and these maintain high binding affinity to folate receptors. 
Folate-FITC and OTL38 are the most widely used conjugates for folate imaging with 
fluorescence emission in the green and near infrared regions of the spectrum, 
respectively. 
  
The aim was therefore to develop a collection of folate conjugates that could be 
evaluated with FR-positive cells. It would be assessed if these imaging agents could 
provide information on the polarisation state of macrophages within the inflamed lung.  
 
 








FR-β has become an investigational tool for targeting myeloid cells since the discovery 
by Nakashima‐Matsushita et al. of its expression on a subset of activated macrophages 
and placental cells.48 It is characterised by having a high affinity for folic acid (Kd = 
10−10 M).40 Since then, FR-β has been reported on monocytes and macrophages in a 
number of different diseases.49-51 The reason for the overexpression of this receptor in 
these cells types is not currently known. It is also known to be present on CD34+ bone 
marrow cells52 and neutrophils,53 however in these cells the receptor is non-functional 
and does not bind folates. This could be due to a post-translational modification in 
these cell types that disrupts its ligand binding ability.  
 
A summary table of evidence of FR-β expression (Table 1) shows the complex nature 
of this biomarker, based on data from a number of different in vitro and in vivo models; 
including studies showing folate mediated uptake in rheumatoid arthritis, osteoarthritis 
and tumour associated macrophages.48, 54, 55 In the lung human tissue samples from 
patients with idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease 
and nonspecific interstitial pneumonia all show an increase of FR-β expressing 
macrophages. Currently, uptake of folate conjugates by pulmonary macrophages has 





Table 1: Evidence of the expression of FRβ in immune cells from human and animal 
samples relevant to certain diseases and the phenotypic markers co-expressed on the 
FR-β positive cells. 
 a Samples were taken from patients with various leukaemia’s 
 
Xia investigated the presence of the folate receptor on activated macrophages from 
arthritic patients.50 Fluorescence imaging was used to show that the folate receptor was 
a valid marker for activated macrophages, while non-activated macrophages did not 
express the folate receptor. After characterising that bacteria-recruited murine 
macrophages expressed FR and that these were activated (upregulation of Ly-6C/G, 
CD80 and CD86), folate-FITC was incubated with the synovial fluid of patients with 
diagnosed rheumatoid arthritis. A subset of the CD11b+ macrophages were found to 
uptake folate-FITC, and competition experiments showed that this uptake could be 
inhibited with free folic acid - showing FR specificity. Finally, a technetium-
Cell type Host 
species 
Activation Phenotypic markers 
present 
Ref. 
Peritoneal Mφ Mouse Bacteria/ 
thioglycolate 
CD80, CD86, Ly-6C/G 50  
Synovial Mφ Human 
rheumatoid 
arthritics 
N/A CD14 48 
Peripheral blood 
monocytes 
Human None/ naive CD16– CD14+ 56 
Lung Mφ 
 





M-CSF CD14, CD68 and 
CD163 
54 






ability to deliver payloads via the folate receptor which could then accumulate in 
inflamed tissues. Atherosclerotic mice (ApoE-/- mice fed a high fat ‘Western diet’) 
were injected via the tail vein with 2 mg/kg of NT-liposome-DiD or Fol-liposome-
DiD, respectively. Fluorescence imaging showed selective uptake of Fol-liposomes in 
atherosclerotic mice (Figure 2.4). 
 
Figure 2.4. Representative images of fluorescent liposomes in an atherosclerosis 
mouse model (ApoE-/-). Mice were injected via tail vein with 2 mg/kg Fol-liposome-
DiD, NT-liposome-DiD, or Fol-liposome-DiD + unlabelled Fol-liposome 
(competition). 12 hours after injection, fluorescence images were acquired on a Kodak 
imaging station (λex = 635nm, λem = 700nm). Adapted from Poh et al.,
57 with 
permission from Elsevier. 
 
Han applied a Cy5 labelled folate probe to an lipopolysaccharide (LPS) murine model 
of acute lung inflammation.49 Healthy and inflamed mice were dosed with the Cy5 
probe and representative fluorescence imaging is shown in Figure 2.5. Flow cytometry 
was used to show that FRβ+ interstitial macrophages and monocytes were responsible 
for probe uptake. The authors concluded that these cells had characteristics of 





synthesised as a tool compound from a reported procedure.41 A folic acid analogue 
with an ethylenediamine spacer was synthesised in high and was conjugated to the 
single isomer of fluorescein-5-isothiocyanate (5-FITC) through a thiourea bond 
(Scheme 2.1). The product was purified by RP-HPLC and lyophilised, giving a 30% 
yield. 
 
Scheme 2.1. Synthesis of FITC-Folate (1). An ethylenediamine spacer was selectively 
added to the γ carboxylic acid group (highlighted) of folic acid. Following Boc 
deprotection under acid conditions (TFA), the free amine was conjugated to the 
fluorophore via a thiourea moiety. 
 
To synthesise a far-red analogue, we decided to conjugate a Cy5 dye to folate. A far-
red fluorophore would be more suitable for in vivo imaging applications given the 
known problems of green autofluorescence from tissues, however there are limited 
examples of far-red folate conjugates.7, 44 The Cy5** fluorophore was chosen as it had 
been demonstrated in a recent clinical study to have suitable solubility, stability, 
25 
 
brightness and clearance when used in vivo.19 Using the amine functionalised folic acid 
previously prepared, the Cy5** folate conjugate was synthesised by reaction with 
Cy5**-NHS that was formed in situ (Scheme 2.2). This required purification by RP-
HPLC giving the probe Cy5**-Folate (3).  
 
Scheme 2.2. Synthesis of Cy5**-Folate (3). Cy5**-NHS was formed in situ with the 
activating agent TSTU (N,N,N′,N′-Tetramethyl-O-(N-succinimidyl)uronium 
tetrafluoroborate) and immediately allowed to react with Compound 2. 
 
Attempts to modify the ethylenediamine spacer with a longer PEGylated spacer gave 
reaction mixtures from which it was difficult to isolate the product. Additionally, poor 
final yields and tedious RP-HPLC purification required after the solution synthesis led 
to an alternative synthetic route being sought. Existing routes involve the 
functionalisation of folic acid to bear an alkyne group for click chemistry58 or its 
hydrolysis to give pteroic acid.59 However, these require further synthetic steps and 
purifications, while the ideal procedure would not require extensive modification of 




2.2.1. FolateTag: generating folate receptor targeting probes 
In order to generate a library of folate compounds, a standard Fmoc solid phase 
synthesis was developed on a polystyrene resin with a Rink-Amide linker. The 
following building blocks were coupled under standard DIC and Oxyma coupling 
conditions: Fmoc-Lys(Dde)-OH, Fmoc-PEG2-OH; then the deprotected terminal 
amine was reacted with a folate NHS ester. The reactive folate NHS ester was 
synthesised using conditions reported by Trindade, that result in higher regioselectivity 
for the gamma-conjugate over the alpha-conjugate in the final product due to formation 
of the cyclic anhydride.58 In the last step, the Dde protecting group was removed by 







Figure 2.8: Absorption spectra of folate-fluorophore conjugates were recorded using 
a Shimadzu UV1800 spectrophotometer. Samples were prepared in PBS pH 7.4. The 
absorption maxima are given for each conjugate (in nm). 
 
Next, the fluorescence spectra were measured. These compare closely to the parent 
fluorophores showing that attachment to FolateTag had caused no change in 



































































































   
 
Figure 2.9: Fluorescence spectra were recorded in PBS solution at room temperature 
using a Horiba FluoroMax fluorometer. The emission maxima are given for each 
conjugate (in nm). Excitation energies: FAM folate:497 nm, NBD folate: 459 nm, 
Cy5** folate: 652 nm, MeroCy-SO folate: 582 nm. Spectra were processed with 
SpectraGryph. 
 
2.3. FR+ cancer cell targeting  
Initial evaluation of the probes was carried out with the KB cell line (ATCC CCL17, 
human cervical carcinoma, subclone of the HeLa line). KB are known to overexpress 


























































































therefore provide a good model for testing target interaction of these probes. Previous 
experience in our group with folate-targeted agents showed it was necessary to use 
folic acid depleted media (FF-RPMI) for cell culture, up to 2 weeks prior to 
experiments. This agrees with reported methods by other researchers, providing cells 
with functional levels of folate receptor expression that are not saturated.60, 61 Cell 
survival is maintained by the minimal level of folic acid present in FBS, which is at  
more physiologically relevant levels in this media (FF-RPMI) compared to the 2 µM 
in conventional RPMI.61 After establishing KB and A549 cultures (as a negative FR-
α control), these were cultured over 2 weeks in folate deficient RPMI media. However, 
as these immortalised cancer cells are presumably adapted to excess folate 
supplementation, over 2 weeks cell proliferation noticeably decreased. 
 
Figure 2.10. FR cell targeting and modes of action, A) Folate probe binding, B) Folate 
probe in the presence of 1000x folic acid, C) Folate probe binding and receptor 
mediated internalisation active at 37 °C. 
 
Each compound was assessed by flow cytometry and live cell confocal microscopy for 
FR receptor-mediated labelling and endocytosis (Figure 2.10). Confocal microscopy 
was performed in a controlled environment (37 oC temperature, 5 % CO2) and cells 
were incubated with nucleus and plasma membrane stains according to manufacturer’s 
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instructions, washed with PBS, then incubated with the folate probe for 15 min at 37 oC 
and subsequently washed with PBS once. A Leica SP5 confocal system was used with 
laser lines 405 nm, 488 nm, 633 nm and tuneable detectors set at 435-460 nm (for 
Hoechst), 500-550 nm (for fluorescein), 640-750 nm (for Cy5). For all microscopy 
studies, except with a Cy5 probe, cells were co-stained with CellMask™ DeepRed 
(Invitrogen) to highlight the plasma membrane. The CellMask™ stains are 
amphipathic dyes that have a lipophilic component which interacts with the cell 
membrane and a hydrophilic dye which localises to the plasma membrane. However, 
long incubation times caused this stain to be endocytosed resulting in additional 
intracellular staining. The results are summarised below for each probe.  
 
FITC-folate 
FITC-folate (1) gave strong cell membrane staining of all KB cells, as expected from 









Figure 2.11. Confocal imaging of KB (left, enhanced size) and A549 control cells 
incubated with 0.5 µM of probe 1. Legend: Probe 1 (green), nuclei (blue) and 






The Cy5** analogue (3) from the initial series of compounds showed bright membrane 





Figure 2.12. Confocal imaging of KB and A549 cells incubated with 1 µM of probe 








With the PEGylated FAM-Folate probe (5), this was highly specific to the cell 
membrane of KB cells. Although the intensity was not as bright as the FITC 




Figure 2.14. Confocal imaging of KB and A549 control cells incubated with 1 µM of 
probe 5. Merge of probe and membrane stain on KB cells shown bottom left. Legend: 








Confocal imaging with the NBD-Folate probe (6) showed very weak staining, 
presumably due to 6 not localising in hydrophobic environments which are necessary 
to switch on the fluorophore. Instead localised intracellular staining was seen. 
Additionally, there was some colocalisation of 6 with the membrane stain. The 








Figure 2.16. Confocal imaging of KB (6 and merge image shown separately) and 
A549 control cells incubated with 1 µM of probe 6. The NBD staining of the cell 
highlighted is shown separately for clarity (below). Legend: Probe 6 (green), nuclei 




Cy5** folate (7) 
 
Figure 2.17. Chemical structure of the Cy5**-Folate probe (7). 
 
Confocal imaging with KB cells showed bright membrane staining with 7 and it did 
not stain A549 cells. 
KB A549 
  
Figure 2.18. Confocal imaging of KB and A549 control cells incubated with 0.5 µM 







Figure 2.19. Chemical structure of the MeroCySO-Folate probe (9). 
 
Confocal imaging was performed with 9, however labelling of KB cells was weak even 
with increased laser power (Figure 2.20, red staining). There was weak intensity cell 
membrane labelling, as seen by the localisation with the green plasma membrane 
staining. Labelling of A549 cells was not seen (not shown).  
KB KB (Merge) 
  
Figure 2.20. Confocal imaging of KB cells incubated with 1 µM of probe 9. Left: 
Nuclei and Probe 9 channels, Right: Merge. Legend: Probe 9 (red), nuclei (blue), and 








Conjugate Affinity (nM) 
1 26 ± 1.1 
3 0.9 ± 0.1  
5 20 ± 6.0 
7 0.9 ± 0.1 
Table 2: Relative affinity (concentration of 50% saturation) was derived for each 
conjugate from the non-linear regression of binding curves generated in Figure 2.23.  
 
From fitting non-linear regression curves, the affinity of each probe could be 
determined. The KD was determined from the concentration of ligand at which half of 
the receptors are occupied (Table 2). Every folate conjugate assessed has a binding 
affinity in the low nanomolar range, with the Cy5 conjugates having higher affinity 
under these assay conditions. This shows that the large fluorophore moiety does not 
interfere with the FRα binding affinity. There was not a large difference in affinity 
between the shorter linker and PEG2 linker (e.g. 26 nM (1) and 20 nM (5)).  
 
2.3.3. Cellular cytotoxicity  
Cytotoxicity of each probe to KB cells was assessed using the CellTitreGlo 2.0 assay 
(Promega) which measures ATP activity that can be directly related to cell viability. 
As expected, very little cytotoxicity was seen at the compound concentrations of 50 
nM to 500 nM for all compounds. The highest concentration used was five-fold higher 
than that used in most functional experiments. In addition, the Pierce LDH (lactase 
dehydrogenase) assay was used to measure possible cytotoxicity based on membrane 
damage by cytotoxic compounds. If cell membranes were damaged then more LDH 
would be released, suggesting higher cytotoxicity of the compound. In the LDH assay, 
there was some LDH release at the highest concentration particularly for 6, suggesting 




levels of FR-α expression (103 to 104 receptor/cell).14, 62 Also, normal lung tissue was 
assessed as a comparison. We selected the best performing FAM and Cy5 probes (5 
and 7) to be evaluated in a multiparameter flow cytometry assay which aims to identify 
the different cell types present in a primary tissue digest (Figure 2.26, carried out by 
Richard O’Connor at the QMRI). In normal lung samples, the probe preferentially 
labelled EpCAM+ epithelial cells. No significant staining was seen on CD45+ cells 
which could be expected as the majority of cells in this population are T cells and 
lymphocytes that do not express folate receptors.49-51 However, when the CD45+ 
population was gated for macrophages that do express folate receptors, some binding 
was apparent. The high expression of folate receptors in normal lung tissues has been 
reported before, however, the quality of adenocarcinoma tumour digest was poor, 
meaning these samples had too few cells to analyse.63 
 
The labelling of normal lung tissue could be a problem for the identification of tumour 
cells in a clinical setting. However, previously developed folate conjugates have been 
reported to not accumulate in the lung. This could be because the folate receptor is 
expressed on the apical membrane which is not exposed to folate image agents 
delivered through the bloodstream in clinical studies. Also, in our experiment it is 




high affinity ligand for folate receptors, to show that binding was due to interaction 
with the folate receptor. Further evidence of folate specific binding was shown with 
FR negative A549 cells that do not uptake the conjugates. 
 
While under the ideal conditions of our in vitro assays these compounds are straight 
forward to assess, it was more difficult to apply in primary lung cancer tissue digests. 
 
2.4. FR+ macrophage targeting 
In collaboration with Tom Speight, we had tried to reproduce work that showed that 
monocyte derived macrophages were capable of binding folate conjugates.64 In 
addition, monocytes themselves should uptake folate conjugates as previously 
shown.56 Macrophages, monocytes, lymphocytes and neutrophils were obtained from 
the buffy coat of healthy blood donors as described in Chapter 1.  
 
Our initial results by flow cytometry suggested low amounts of binding occurred to 
the folate receptor, as the overall change in fluorescence was small. Secondly, there 
was not a significant amount of binding to macrophages and lymphocytes compared 
to the non-targeted Cy5 dye that used as a control condition (Figure 2.27). It appeared 
that non-receptor mediated events dominated in the case of monocytes, as we were 
unable to compete probe binding to this cell type (Figure 2.27C). It is worth noting, 
in this experiment a concentration of 1 µM Cy5**-Folate probe was used, as we 
believed this would be enough to saturate any available receptors. In this experiment, 
differentiation of macrophages was carried out with autologous serum and this may 






cell surface expression. However, after antibody staining the fluorescence signal 
(MFI) was lower than the unstimulated population. Compared to an isotype control, 
neither antibody signal showed a significant level of fluorescent increase/binding, 
suggesting that the binding seen was non-specific and/or the receptor was not highly 
expressed. 
 
In order to confirm the findings and given the lack of validation data for the PE-FOLR2 
antibody used for flow cytometry, a Western blot was carried out with another 
antibody. Cell lysates from NR8383 and A549 cells (a negative control for FR-β) were 
prepared using a lysing buffer (RIPA buffer with protease inhibitor cocktail). Total 
protein concentration in the lysate was quantified using the Bio Rad DC colorimetric 
assay. Immunoblotting with an anti-FOLR2 antibody was carried out with a range of 
antibody dilutions (1:500 – 1:2000) and total protein concentrations, however no band 
corresponding to the target protein (~37 kDa) was seen for either cell type (Figure 
2.30). This suggested that under the conditions tested NR8383 cells did not express a 






range of concentrations used to determine target binding specificity. The focus was on 
Cy5**-Folate 7, as it would be more applicable in the lung due to its far-red emission.  
 
Flow cytometry macrophage assays were performed with Cy5**-Folate (Figure 2.35). 
Incubation of serial dilutions of 7, with and without receptor blocking, were measured 
and the fluorescence intensity plotted as an isotherm. With the M2 MDMs it was 
possible to detect cells which bound 7, although this was a heterogeneous population 
representing 77% of total cells when stained with 50 nM of 7. The sensitivity of the 
probe in this assay was also highlighted by the ability to detect FR+ cells with 50 nM 






phenotyping ability of this probe. Importantly, this in vitro experiment only represents 
two populations of cells that would be found in the lung and so further imaging would 
be necessary on inflammatory cells present in the human lung.  
Figure 2.38. Zoomed image of the apparent cytoplasmic concentration of 
Cy5**-Folate shown in Figure 2.37C. 
 
Additionally, GM-CSF or M-CSF are not always seen as activation stimuli of 
macrophages but generate a resting state. Further stimulation might be necessary to 
generate macrophages representing classical and alternative activation states – with 
microbial LPS and/or IFN-γ (a T helper 1 cytokine), or IL-4 and IL-13 (T helper 2 
cytokines).71  In a pilot experiment to look at the response of M-CSF macrophages to 
stimuli, cells from one donor were polarised with M-CSF and then stimulated further 
with either LPS (100 ng/mL) or IL-4 (20 ng/mL), for 24 hours respectively. Each well 
was stained with either Cy5**-Folate or PerkinElmer FolateSense (a commercial 
probe for folate receptors). Microscopy and automated image analysis was performed 
on the CellInsight system (ThermoFisher). An analysis algorithm was used to calculate 
the average intensity of fluorescent probe in each cell (Figure 2.39). The data shows 
some correlation with the findings of Puig-Kröger that IL-4 increases FOLR2 mRNA 
levels, while LPS does not greatly decrease cell surface levels of FRβ. Although in our 





Figure 2.39. Image analysis of the M-CSF macrophage stimuli panel with the Cy5**-
Folate and FolateSense probes (100 nM 7 and 25 nmol FolateSense). The nucleus was 
labelled with 1 µg/mL Hoechst 33342 for segmentation. Data represents the average 
intensity per object detected from at least 3 wells per condition. N=3, mean ± SD. 
 
2.4.4. Folate mediated internalisation 
As imaging data suggested that the uptake of the probe was rapid and it was mostly 
internalised, we looked at the dynamics of labelling over time. Timelapse imaging of 
M2 MDMs was used to show whether only a population of cells uptake the probe, as 
seen by flow cytometry. This would reveal any morphological differences of the cells 
that were responsible for probe uptake. With an environmentally controlled confocal 
microscope, cells were dosed with 250 nM Cy5**-Folate and observed over 15 hours 
(Figure 2.40). A difference with the previous imaging experiment was that the media 
contains the fluorescent probe continuously, rather than it being removed after 30 
minutes. After 30 minutes the fluorescent signal was accumulated in cells in the top 








































In the lung it may be more suitable to study interstitial macrophages – a population 
recruited from peripheral monocytes following lung injury. 
 
Initially, aged mice were investigated for FR-β (FOLR2) expression by flow 
cytometry. Using an established flow cytometry assay, peritoneal cells were retrieved 
from mice and then immunophenotyped, with macrophages determined by their 
CD11b+ status. The population of monocyte-derived macrophages were selected based 
on their marker status as F4/80high and MHC class IIlow; with the remaining smaller 
population of F4/80low/ MHC class IIhigh macrophages being resident macrophages. In 
the F4/80high/ MHC class IIlow population, a percentage of cells were FR-β positive. 
When Cy5**-Folate was applied in this flow cytometry assay, a clear correlation 
between FR-β antibody and Cy5**-Folate positive cells was seen (Figure 2.40A).  
 
Competitive binding experiments used previously (labelled ‘Probe +FA’) also showed 
the probe was specific to the FR-β+ subset, while a small percentage of FR-β– cells 
also bound the probe. The experiment was reproduced with five mice, giving 
significant changes between the control and probe (p ≤ 0.0001), and probe +FA (p ≤ 






express significant levels of FR-β. Together this data shows that an optimal 
concentration of probe needs to be determined to avoid binding through non-specific 
processes. Probe 7 (50 nM) can detect FR-β+ M2 macrophages in a flow cytometry 
assay. Additionally, 7 shows selectivity to an M2 phenotype of macrophage over M1 
macrophages, showing the probe could be useful for the detection of tumour associated 
macrophages in the tumour microenvironment. This probe was also able to detect 
folate receptor beta positive macrophages in peritoneal macrophages, showing it could 
be valuable for macrophage imaging outside of the lung. 
 
2.6. Further work 
The next steps for the use of folate Smartprobes include imaging in a whole lung 
model. Due to the challenges of generating a FR positive population in vitro, it is 
difficult to say how these results would translate into an in vivo setting. While the 
results show folate receptor expression is upregulated in the presence of the cytokine 
M-CSF, without further evaluation it is not possible to say if this represents a 
macrophage phenotype. Additionally, there is differential expression across the 
populations of monocyte-derived macrophages tested, which may bring challenges to 
determining the relevance of this marker in disease.  
 
The use of primary murine cells highlighted that in aged mice a small population of 
peritoneal macrophages are FR-β positive and these can bind folate conjugates. 
Similarly, it would be expected that an inflammatory stimulus (such as LPS or 
zymosan) would increase the number of F4/80+ macrophages found in this model. The 
future direction of this work is to optically image mice following intraperitoneal 
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injection of the compound, to show that the accumulation of probe can be detected in 
the peritoneal cavity. Additionally, carrying out an in vivo mouse inflammation model 
would help to determine the function of FR+ macrophages in the peritoneal cavity. 
The immune cell populations from healthy and inflamed mice could be observed by 
flow cytometry and the relative levels of FR-β positive cells between groups 
compared. After this, using genetically engineered mice to knockout FR+ 
macrophages could hypothetically be a method to understand the importance of these 
cells in the inflamed peritoneum.
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3. Macrophage nanobody probe 
The macrophage mannose receptor (MMR), also known as CD206, is a carbohydrate 
binding receptor expressed by certain populations of macrophages and dendritic cells.2 
Its roles include the clearance of endogenous molecules (by internalisation and 
degradation in lysosomes), promoting antigen presentation, modulation of activation 
and trafficking. It has a number of endogenous ligands including myeloperoxidase, 
tissue plasminogen activator, thyroglobulin and hepatocyte growth factor β-chain, and 
is characterised by two carbohydrate binding domains. These recognise sulfated and 
mannosylated sugars, and a number of C-type lectin like domains (CTLDs), which 
bind carbohydrates with terminal mannose, fucose or N-acetylglucosamine (GlcNAc) 
units.2 MMR is a member of an receptor family that endocytose their ligands and it is 
the only member of this family to have a cysteine rich (CR) domain that binds sulfated 
galactose or N-acetylgalactosamine (GalNAc) through a recognition motif on a 
sulfated N-acetylgalactosamine terminated sequence.72 MMR plays a role in collagen 
internalisation in macrophages, through recognition of collagens I – IV by its 
fibronectin type II domain (FNII), which also recognises exogenous molecules such 
as microbial particles from bacteria, fungi and viruses.2 
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Figure 3.1. Representation of the mannose receptor showing the structural properties 
with three types of extracellular domains. CR, cysteine rich domain; FNII, fibronectin 
type II domain and CTLDs, C-type lectin like domains. 
 
In a cellular context, the mannose receptor recycles constantly between the plasma 
membrane and early endosomal compartments, with most of the receptor being 
intracellular.73, 74 MR mediated endocytosis is clathrin-dependent, a form of vesicular 
transport that involves internalisation and receptor recycling. Clathrin proteins are 
responsible for polymerising around the budding cytosolic face of the membrane, 
initiated by the accumulation of so called ‘adapter proteins’, while endosomal 
acidification induces ligand release and subsequent receptor recycling. The mannose 
receptor is not involved in phagocytosis, as over expression in mouse macrophages 
did not affect the uptake of particulate ligands.75 Actin polymerisation (commonly 
inhibited by cytochalasin D) may be required for mannose receptor recycling, as 
shown by studies where receptor expression was modulated by cytochalasin D.76 This 
suggests inhibitors commonly used for distinguishing phagocytosis may affect MMR 
function. The mannose receptor also has a role in signalling and modulating activation 
through toll-like receptors (TLR) and Fragment, crystallisable receptors (FcR), which 
70 
 
needs to be considered as ligating this receptor could lead to cross-linking of the MR 
and FcRs.77 
 
As explained in Chapter 1 macrophages can be polarised by environmental stimuli. In 
vitro, MMR expression is increased in human macrophages undergoing M2-like 
activation (e.g. treatment with IL-4, IL-13 or IL-10).32 In vivo, major 
histocompatibility complex (MHC) class II low, M2-like TAMs are present in lung 
and breast carcinoma’s and MMR’s are upregulated on these TAMs,78 making them 
angiogenic, immunosuppressive and tumour promoting. Additionally, macrophages in 
the tumour environment are known to contribute to cancer progression and poor 
prognosis in many human tumours.79, 80 Mannose receptors have also been used as a 
biomarker of M2 polarised macrophages in COPD patients, with increased MMR+ 
alveolar macrophages correlating with smoking and COPD severity.81 Due to the 
relevance of this receptor in the pathologies discussed, methods to image MMR+ 
macrophages would be a valuable diagnostic tool. 
 
3.1. MMR targeted imaging agents 
A number of different approaches have been taken to designing probes against CD206+ 
macrophages, from antibodies to a more recent report of a target-binding peptide. The 
Manocept agents developed by Navidea Biopharmaceuticals are glucose polymers 
appended with mannose and are imaging agents targeting the lectin domain of CD206. 
One of these agents called γ-Tilmanocept has been FDA approved which is an 99mTc-
labeled radiolabelled tracer for the imaging of sentinel lymph nodes.82 A similar 
strategy was applied by Kim who developed a near-infrared MMR targeting polymer 
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and utilised using NIR optical coherence tomography to visualise carotid atheroma 
plaques.83 However, mannose derivatives are not specific to CD206 and can be 
recognised by other mannose receptors such as DC-SIGN on dendritic cells.84 
Therefore, there is a desire to develop different ligands that are more specific to CD206 
which are suitable for use in the clinic. Recent developments have included nanobody 
ligands and MMR-targeted peptides.85, 86 
 
3.1.1. Nanobodies as imaging probes 
In 1993, Muyldermans et al. reported the first nanobodies, also known as single 
domain antibodies (sdAb). These contain only variable domain heavy chains (VHH 
domain, ~15 kDa) and are isolated from the serum of immunised camelids.87 
Nanobodies have since been developed as imaging tracers (radionuclide, optical and 
ultrasound) against a number of targets in oncology and inflammation88-91 due to their 
high affinities, small size and good physicochemical properties.92 They represent an 
alternative to monoclonal antibodies (mAb) because of their comparable antigen 
affinities, while their small size (~15 kDa) avoids the long circulation times that hinder 
the applications of mAbs for imaging (Figure 3.2). Additionally nanobodies have low 
immunogenicity due to sharing high identity with the human type 3 and 4 VH domain 
families and have been humanized.93 These features are being exploited in drug 
discovery, with a number of nanobodies in clinical development for diverse targets.94 





Figure 3.2. Size comparison of a mAb and nanobody (sdAb). 
 
Figure 3.3. Overview of the in vivo phage display of nanobodies. After immunisation 
of a camelid, cDNA is isolated from the animal’s lymphocytes. The cDNA is 
introduced into a phagemid and used for panning against the antigen of interest. 
Positive clones are expressed in a desired format. Reproduced from Schoonooghe.95 
Copyright 2012, with permission from Elsevier. 
 
The in vivo phage display of nanobodies (Figure 3.3) was carried out by immunising 
camelids (in this case an alpaca) with human MMR. After immunisation, blood was 
taken from the animal and mRNA extracted from peripheral blood lymphocytes. The 
gene sequences for the variable domains were PCR amplified, ligated into a phagemid 
vector that codes for a HA with a His tag to allow purification of the nanobody. Phage 
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display is carried out by transforming the vector into a host cell such as E.coli. With 
the variable domain of heavy chain antibodies (VHH) library obtained, the desired 
VHHs were obtained by panning. The VHH library was expressed on phage and 
enriched by selection with antigen coated plates. In a second round of biopanning, 
bound phage particles were used to infect E.coli and subsequently the periplasmic 
extract of each clone was tested for target affinity in a human MMR ELISA. The 
desired nanobody could then be produced, commonly in E.coli. The complementarity 
determining regions  (CDRs) of nanobodies play a role in maintaining their stability 
and binding affinity.96 
 
3.1.2. MMR nanobody 
Nanobodies represent the most advanced agents for CD206 targeting that have shown 
promise as molecular imaging agents.97 Movahedi produced a 99mTc-labelled 
nanobody against MMR with an affinity of 2 nM determined by SPR and validated its 
use for SPECT/micro-CT imaging of tumour-associated macrophages (TAMs) in 
preclinical models.91 SPECT/CT imaging in tumour-bearing mice showed uptake of 
the nanobody which was significantly higher than uptake of the control nanobody with 
analysis of the dissected tissue confirming these findings.  
 
This nanobody was further developed by Blykers as an 18F-PET tracer for the detection 
of macrophages in tumour stroma.85 TAMs with upregulated CD206 were found to be 
tumour promoting. In vitro studies with 18F-benzoic acid labelled nanobody (anti-
MMR 3.49) showed it had high affinity for human MMR (KD = 1.8 nM), while in vivo 
biodistribution studies showed rapid renal clearance and specific retention in the 
74 
 
tumour and MMR-expressing tissue. In a small animal PET imaging study, the 
nanobody was specifically recognised by MMR in 3LL-R tumour bearing mice, when 
compared with the uptake in MMR-deficient mice. (Figure 3.4)  
Figure 3.4. Transverse and coronal PET/CT images of WT (left) vs. MMR-deficient 
(right) 3LL-R tumor–bearing mice scanned 3 h after injection of 18F-benzoic acid 
labelled-anti MMR 3.49. Arrows point to the tumour (T), kidney (K), and bladder (B). 
Adapted with permission from Blykers et al. Copyright 2015 Society of Nuclear 
Medicine and Molecular Imaging.85 
 
This ligand shows promise as a radiopharmaceutical due to its ideal properties and the 
ease of radiolabelling, while it could also be developed as an optical probe for 
highlighting M2 macrophages during fluorescence-guided surgery. As noted by Debie 
et al. the fluorophore chosen and method of conjugation should be carefully considered 
when developing labelled nanobodies.98 
 
3.1.3. Peptide imaging agents 
Fluorescent peptides are a widely utilised method for labelling receptors and a number 
of peptidic agents are under clinical investigation for cancer and bacterial infection 
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imaging.24 There are a number of reports of peptides that bind CD206, including a 10-
mer peptide RP-182 developed by Riptide Bioscience, however this is not specific as 
it also binds a number of other receptors.99 Recently, Scodeller et al. showed that M2-
like TAMs could be targeted by a ‘FAM-UNO’ fluorescent cyclic peptide (sequence: 
5(6)-FAM-Ahx-CSPGAKVRC).86  
 
3.2. Optical MMR nanobody probe 
The work presented is a collaboration between myself, Tom Speight, Edinburgh 
Molecular Imaging and Vrije Universiteit Brussels. The MMR targeting nanobody 
(clone 3.49) used in the study by Blykers obtained had the properties below.85  
 
Table 3.1. Properties of the batch of nanobody used. 
 MW (Da) ε (M-1cm-1) Concentration (mg/mL) 
MMR 3.49 12,682 24,660 3.805 
 
The protein sequence has been published and is given below with the CDRs 
highlighted in grey.100 As a random lysine labelling would be carried out, it was 




Blykers used surface plasmon resonance (SPR) to calculate the kinetic and equilibrium 
properties of the nanobody to recombinant MMR protein (Table 3.2). The binding 
affinity was 1.8 nM, showing that the nanobody expressed had high affinity for its 
target. 




Table 3.2. Binding kinetics of the nanobody to hMMR by Blykers.85 
 ka (M-1 s-1) kd (s-1) KD (nM) 
MMR 3.49 4.4 x105 8.0 x10-4 1.8 
 
3.2.1. MMR nanobody labelling 
Fluorophore labelling of this protein was carried out under mild conditions with the N-
hydroxysuccinimidyl (NHS) reactive ester of the dye, which reacted with lysine 
residues forming an amide bonds between the protein and the fluorophores. It was 
important to test the conjugation conditions due to the limited amount of nanobody. 
Initially, lysozyme was chosen as a model protein due to its similar size and 
availability. This protein was successfully labelled with the far-red Cy5** active ester 
[see data in Chapter 6.4]. Conjugation conditions were optimised for pH and reaction 
time. 
 
Initial attempts at fluorophore labelling nanobody 3.49 were carried out using this 
validated procedure. However, labelling with the Cy5** fluorophore gave poor levels 
of protein labelling. The reason for this is not fully understood as the model protein 
reactions were successful. Instead when the SulfoCy5 dye was used the levels of 









𝑑𝑒𝑔𝑟𝑒𝑒 𝑜𝑓 𝑙𝑎𝑏𝑒𝑙𝑙𝑖𝑛𝑔 (𝑑𝑦𝑒 𝑝𝑒𝑟 𝑝𝑟𝑜𝑡𝑒𝑖𝑛) =  
𝐴𝑚𝑎𝑥 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
𝜀′ × 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐. (𝑀)
 
Equation 3.2. Calculation of degree of labelling, where ε’ is molar extinction 
coefficient of the dye. 
 
 
SDS PAGE was ran for both the labelled and unlabelled forms of the protein, however 
standard glycine gels did not have the separating ability to resolve the small size of 
this protein. Thus a tricine gel was used with 0.5 – 1 μg of protein loaded in each lane 
in reduced sample buffer, which gave a clearer band for the unlabelled and labelled 
proteins when visualised with Coomassie staining (Figure 3.11). However, the change 
in position of the band was not clear due to the relatively small change in total protein 
size after fluorophore labelling. 
 
Figure 3.11. SDS-tricine PAGE under reducing conditions (10% separating: 3% 
stacking gel) visualised with Coomassie staining. The lanes correspond to lane 1 
(standards ladder), lane 2 (0.5 μg unlabelled MMR), lane 3 (1 μg labelled MMR, Cy5-
Nb) and lane 4 (0.5 μg labelled MMR, Cy5-Nb) with the pink marker showing the 




The fluorescence spectrum of Cy5-Nb in PBS showed that the nanobody was labelled 
with the dye and that this labelling had not changed the emission properties of the 
SulfoCy5 fluorophore (Figure 3.12). 
Figure 3.12. Fluorescence spectra of SulfoCy5 dye excitation (dashed red) and 
emission (dashed black) and Cy5-Nb emission (solid black). Solutions were prepared 
in PBS, 1 µM, excitation = 640 nm. 
 
3.3. Cellular labelling 
Biological studies with this probe were performed by Tom Speight with the aim to 
study the specificity of the probe for macrophages using an established model of 
human macrophages derived from healthy blood donors. Firstly, expression of CD206 
was examined in monocyte-derived macrophages (MDMs) after 6 days in culture. The 
CD206 receptor was significantly upregulated once monocytes were differentiated to 
macrophages (Figure 3.15). However, in the presence of common polarisation stimuli 
(LPS, IL-4, M-CSF, dexamethasone) no difference in receptor expression was seen – 
suggesting CD206 cannot be claimed to represent an M2 macrophage activation 



















With neutrophils Cy5-Nb uptake was observed, however there was also uptake of the 
non-conjugated Cy5 dye. This suggested non-specific uptake was responsible for the 
labelling and could be explained in a number of ways; neutrophils may recognise the 
Cy5 dye in some manner, alternatively it could be via phagocytosis and recognition of 
foreign material by Fc receptors, which a major responsibility of neutrophils in their 
function as phagocytes.101 As neutrophils are recruited in the lung by inflammatory 
stimuli, this off-target binding should be considered for preclinical applications of this 
probe in inflammatory disease models. 
 
3.3.1. Receptor-mediated internalisation 
There are a number of cellular uptake pathways, however mannose receptor uptake is 
via clathrin-dependent endocytosis.1 We investigated if Cy5-Nb underwent uptake via 
the same method as it appeared to be internalised within macrophages and this differed 
to the labelling profile of a commercial PE-conjugated antibody for CD206 (Figure 
3.15). This difference in labelling could be due to the smaller size of the nanobody 
allowing more rapid internalisation or an alternative pathway. To our knowledge the 
endocytic capability of the mannose receptor has not previously been shown with this 
ligand.  
 
To generate images of the precise localisation of the nanobody within a cell spinning 
disk microscopy was used. By using multiple pinholes, spinning disk microscopes are 
able to obtain confocal resolution images at a much faster speed than a confocal 
scanning system. This is useful for live cell imaging as it gives the ability to observe 
dynamic events. In this experiment, cells were prelabelled with CellTracker Green and 
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Cy5-Nb. Cell representations were generated using the “Kinder Egg” model in Imaris 
(Figure 3.17). The 3D images show clearly that the majority of fluorescence signal 
from Cy5-Nb is located intracellularly, agreeing with previous results that the majority 
of the receptor is intracellular.73, 74 In the 3D visualisations the probe is also seen 
throughout the cytoplasmic compartment. 
 
 
Time-lapse confocal imaging was used to evaluate the kinetics of the probe labelling 
on macrophages and to show how quickly it bound (Figure 3.18). As this imaging was 
carried out without any washing step, it shows the advantage of having a highly 
specific imaging probe generating a high signal/noise ratio. 
  
  
Figure 3.17. 3D visualisation of macrophage labelling generated using spinning 
disk microscopy and analysed by the Kinder Egg model in Imaris. Left: 
macrophages labelled with CellTracker Green to allow masking of each cell, Right: 
50 nM Cy5-Nb probe fluorescent signal (shown in magenta) in a macrophage. A 
video file showing the imaging from different fields of view is available in the 








was previously demonstrated as clathrin-dependent, however there are alternative 
dynamin-independent methods of endocytosis which could explain why the probe 
signal was not inhibited.  
 
Our inhibition studies did not consider other methods of uptake such as caveolae 
dependent endocytosis. Caveolae mediated mechanisms could be studied with a 
tyrosine kinase inhibitor that prevents caveolae formation.105 These studies would be 
needed to rule out this mechanism. 
 
3.5. Primary macrophages 
We also had the opportunity to test this probe on primary ex vivo patient samples. A 
bronchoalveolar lavage (BAL) from a human lung was taken, consisting of 
predominantly alveolar macrophages and provided an ideal model for testing 
macrophage probes. With BAL, a large percentage of cells were labelled by the 
nanobody probe (Figure 3.23), additionally, cells from an IPF patient contained a large 




Characterisation with BAL clinical isolates from COPD patients showed that Cy5-Nb 
was able to detect a large number of MMR+ cells in these samples, demonstrating the 
potential application of MMR nanobodies in monitoring inflammatory diseases. The 
probe is the first example of a fluorescent nanobody specific to macrophages, 
justifying its further preclinical development. 
 
3.7. Further work 
There are several further experiments needed to validate this probe before clinical use. 
To show applicability to humans, imaging needs to be performed in a whole lung 
model to show that sufficient probe signal can be detected in such a complex 
environment. Nanobodies are still in their infancy, in 2019 the first nanobody received 
FDA approval called Caplacizumab, for the blood clotting disorder acquired 
thrombotic thrombocytopenic purpura (aTTP).94 Studies are necessary to understand 
the potential toxicity and immunogenicity of using a nanobody imaging agent; 
although Caplacizumab was demonstrated to have low immunogenicity. This 




4. Beta-galactosidase probes 
4.1. Cellular senescence 
Cellular senescence is a process of cellular aging and a state of growth arrest. Its 
function is to prevent damaged cells proliferating and to indicate the need for tissue 
repair. Senescence can be induced by telomere shortening, often referred to as 
replicative senescence, or telomere-independent signalling which is often 
characterised by DNA damage or oxidative stress and is called stress-induced 
senescence. Senescent cells accumulate in certain tissues and this is evident in both 
disease states and aging processes, e.g. osteoarthritis, fibrosis.106 A model of the main 
stages of senescence is illustrated in Figure 4.1. 
 
Tissue remodelling plays a key role in the pathology of chronic airway diseases, for 
example idiopathic pulmonary fibrosis (IPF) leads to a progressive loss of lung 
function and is characterised by a loss of epithelial cells, increased interstitial 
fibroblasts and evidence of wound healing.107 In 2014 Tsuji looked at whether cigarette 
smoke exposure induced cellular senescence of alveolar epithelial cells,108 and showed 
cigarette smoke contributed to oxidative stress induced senescence and reduced 
epithelial proliferation. More recently, serum from COPD patients was found to endow 
a senescent phenotype on bronchial epithelial cells when cultured in vitro.109 In parallel 
with the increased understanding of cellular aging, there is growing interest in the 
discovery of compounds (referred to as senolytics) that can impact pathways that cause 
these processes. For example, targeting senescent cells has been demonstrated to 




Figure 4.1. A proposed model of senescence. Senescence initiates tissue remodelling 
by recruiting immune cells through the senescence-associated secretory phenotype 
(SASP). Immune cells clear senescent cells and progenitor cells regenerate the 
damaged tissue. The senescence-clearance-regeneration process may be impaired by 
persistent damage, pathological states or ageing. In these cases, senescent cells are not 
efficiently cleared and the tissue is not fully regenerated. Instead the damage response 
leads to scarring and fibrosis. Reproduced by permission from: Nature Reviews 
Molecular Cell Biology, Muñoz-Espín.111 Copyright 2014 Springer Nature. 
 
A key feature of senescent cells is their increased beta-galactosidase (β-Gal) enzyme 
activity. β-Gal is an enzyme responsible for the hydrolysis of lactose to galactose and 
glucose. Due to its role in energy production, there is a low level of endogenous β-Gal 
in proliferating cells, however it accumulates in senescent cells.111 This has been 
refered to as ‘senescence-associated β-galactosidase’ (abbreviated: SA-βGal) and is 
distinguishable from endogenous galactosidase as it is localised in lysosomes. Kurz 
determined its activity at pH 6.0 was caused by increased lysosomal biogenesis,112 and 
in senescent endothelial cells the activity of SA-βGal was three to six times higher 
than proliferating cells. Other features of senescent cells include changes in 
morphology, increased lysosomal mass and expression of markers such as p16INK4A, 





4.1.1. Alveolar macrophages 
Another cell type that expresses β-Gal are alveolar macrophages which are enriched 
in lysosomal β-galactosidase.114 The relative concentrations of this enzyme during 
epithelial cellular senescence is unclear as this has not been reported, however it would 
be useful to understand as the interactions between leukocytes and the epithelial barrier 
are a key feature of lung immunology. Recently it was reported by Qiu that M1 
activated macrophages, which typically have increased glycolysis, may develop into a 
senescent state with knocking out guanylate binding protein (Gbp1) in RAW264.7 
macrophages associated with significantly higher levels of phosphorylated p53, 
AMPK and increased β-Gal staining.115 Despite alveolar macrophages and epithelial 
cells both expressing β-Gal, an in vivo method of detecting senescent cells would be a 
useful target. 
 
4.2. Beta-galactosidase activity probes 
The development of activatable fluorescent probes for senescence has mostly focused 
on detection of SA-βGal activity. However, historically there has been a wide interest 
in detecting the accumulation of β-galactosidase in primary ovarian cancers,116, 117 and 
its use in molecular biology as a marker of transcriptional regulation.118 The gold 
standard test for β-galactosidase is colorimetric 5-bromo-4-chloro-3-indoyl β-
galactopyranoside (X-gal) staining, although this requires a lengthy process of cell 
fixation, overnight staining and manual counting.113 In contrast, fluorescent probes are 
more sensitive, their readouts can be readily quantitated and they can be used with live 
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cells. For these reasons, the detection of SA-βGal is a valuable target for fluorescent 
probe development. 
 
There are a number of existing compounds to detect the activity of β-galactosidase and 
the area was recently reviewed by Liu.119 These probes are often based on the 
mechanism of β-Gal catalysing the hydrolysis of β-D-galactosides to release 
fluorescent alcohols or phenols. The most widely known probe is C12FDG (Figure 
4.2) – a galactosylated hydrophobic fluorescein that is cell permeable and often used 
for flow cytometric detection of senescent cells.112 This compound is non-fluorescent 
until hydrolysis of the galactosyl groups. Commonly, the fluorescent properties of such 
molecules are quenched by O-galactosylation due to intramolecular charge transfer 
(ICT). This O-galactosylation masks the electron donating groups which contribute to 
fluorescent emission. A number of recent fluorescent probes are summarised below 




Figure 4.2. Chemical structures of a selection of recently reported fluorescent β-Gal 
probes including GalPro,124 C12FDG,112 DCM-βGal,120 AHGa121 and HMRef-βGal.116  
 
Gu developed a ratiometric NIR probe (DCM-βgal) using the large Stokes shifted 
4-(Dicyanomethylene)-2-methyl-6-(4-dimethylaminostyryl)-4H-pyran (DCM) dye 
which allowed imaging of a colorectal tumour in real-time.120 Notably this probe 
required solubilisation with 30% DMSO in PBS, suggesting poor solubility. A 
napthalimide-based two-photon probe (AHGa) for detecting senescence was designed 
by Lozano-Torres using a napthalimide-L-histidine scaffold with a hydrolysable N-
glycosidic bond.121 This was applied for in vivo detection of senescence in mice 




Asanuma synthesised a β-Gal probe based on a xanthene HMRef-βGal.116 By 
optimisation of the fluorophore to reduce background interference they developed a 
probe which had good cell permeability. Upon enzymatic cleavage this probe 
generates a remarkable 1420-fold fluorescence enhancement due to release of the 
highly fluorescent rhodol dye (Scheme 4.1). HMRef-βGal was able to detect β-Gal 
activity in ovarian cancer lines and peritoneal metastatic tumours of <1 mm during in 
vivo fluorescence guided surgery.  
 
 
In order to reduce the cellular leakage of HMRef-βGal, Doura synthesised a probe 
(SPiDER-βGal) for the detection of lacZ(+) cells.122 A weakness of their previously 
developed HMRef fluorophore was that it tended to diffuse and leak out of cells upon 
activation. To prevent this, SPiDER-βGal was designed to undergo a reaction with 
cellular nucleophiles via a quinone methide intermediate after activation by β-
galactosidases (Scheme 4.2). This probe gave single-cell resolution of enzyme activity 
in HEK cells expressing the lacZ reporter and in ex vivo imaging of wing disks from 
Drosophila melanogaster and brain slices of mice. Although this probe was highly 
optimised, it was never applied in models of cellular senescence to detect SA-βGal. In 
Scheme 4.1. Hydrolysis of the quenched HMRef-βGal probe by β-galactosidase gives the 
fluorescent product HMRef and galactose as a by-product. 
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addition, the use of a green fluorophore would be problematic for clinical applications, 
as discussed in Chapter 1. 
 
Scheme 4.2. SPiDER-βGal probe showing when the galactoside moiety is cleaved the 
probe can bind to intracellular proteins (shown in blue) and this occurs along with the 
activation of fluorescence (SPiDER). 
 
Hemicyanines are a recent development in the class of cyanine fluorophores and have 
near-infrared emission, moderate quantum yields, good brightness and low 
photobleaching.123 They have been used as activatable fluorophores due to the 
presence of a hydroxyl group within the conjugation structure of the molecule that can 
be functionalised to give a quenched intramolecular charge transfer (ICT) system 
(Scheme 4.3).10 Additionally, they were synthesised in a single step from the IR780 
cyanine 7 dye. Zhang developed a near infrared probe for β-galactosidase (GalPro) by 





Scheme 4.3. GalPro has a O-galactose moiety that forms a quenched ICT system. 
After cleavage of the galactose unit by β-galactosidase the fluorescent phenolate is 
liberated, giving an extended conjugation system within the hemicyanine dye and 
removal of the ICT system. 
 
GalPro has properties such as NIR emission at 703 nm, a 12.8-fold fluorescence 
increase upon glycosidic cleavage and a limit of β-Gal detection of 0.057 nM.124 In 
comparison to other reported probes (Table 4.1), it had a higher catalytic efficiency 
(kcat/Km) than the DCM-βgal and FDG probes. 
 















685 nm 1.7 x10-4 
U/mL 
60.1 4.8 x105 120 




FDG 520 nm N/A 10.2 1.6 x104 125 




Although most of the probes generated are capable of sensitively detecting 
β-galactosidase, only a few have been applied to detect SA-βGal. GalPro was used for 
the detection of SA-βGal in fibroblasts where premature senescence was induced with 
hydrogen peroxide, however a limited amount of biological data was reported and this 
model does not truly represent epithelial cell senescence.  
 
While some of the reported probes can detect cellular senescence, it is not clear 
whether the models used reflect the complexity of the senescence phenotype in vivo. 
For this project a β-Gal probe was needed that could detect senescent epithelial cells 
and that had suitable physiochemical properties for in vivo lung imaging. Therefore, 
the ideal properties a β-galactosidase probe would be far-red/NIR emission for low 
background fluorescence and specifically turned-on by β-galactosidase in senescent 
epithelial cellular models. Synthesising a galactosidase probe would be a good starting 
point for investigating SA-βGal. 
 
4.3. Synthesis of hemicyanine probes 
Following on from the work of Zhang, two NIR galactosidase activatable probes were 
synthesised. The commercial cyanine dye IR780 was initially synthesised (Scheme 
4.4) and then transformed into the hemicyanine dye by retro-Knoevenagel 
condensation with 1,3-dihydroxybenzene or 4-bromo-1,3-dihydroxybenzene. The 
mechanism of this reaction is shown in Scheme 4.5. The galactosyl moiety was 
appended in two steps; O-galactosylation of the phenol with galactose pentaacetate 





Scheme 4.4. Synthesis of cyanine 7 dye IR780 by condensation of the indolenine salt 
with the dianil linker. 
 
Scheme 4.5. Reaction mechanism for the formation of the hemicyanine dye XD-OH. 
Although the first step is shown as an SN2’ mechanism. IR780 is reacted with 1,3-
dihydroxybenzene in the presence of K2CO3 as base at 50 °C. The first step is a 
nucleophilic substitution, followed by the retro-Knoevenagel leading to the 
elimination of a trimethyl-indole group. This allows for a ring-formation with 




The probes were purified by prep-TLC or RP-HPLC as the deprotected sugar is highly 
polar (see Table 4.2). The GalPro compound synthesised by Zhang is referred to as 
XD-BGal in this work. A variant containing a bromine was synthesised in parallel 
called XD-Br and its galactosyl analogue XD-BrBGal. The partition coefficients 
(clogP) were calculated using the molinspiration program to give an idea of the 
lipophilicity of these probes and whether they would be likely to permeate cell 
membranes. 
 








Table 4.2. The properties for the four compounds synthesised. clogP was calculated 




















The synthesised probes were more hydrophobic than desired and attempting to 
dissolve these entirely in water or PBS solution resulted in precipitation. Therefore, it 
was necessary to dissolve the stock solutions in DMSO. It would be desirable to 
improve the properties of these dyes because the use of solvents such as DMSO are 
not optimal for human applications. A more soluble probe would be predicted to have 
a lower logP value. 
 
4.4. Photophysical properties 
The photophysical properties of each molecule were characterised by UV-Vis and 
fluorescence spectroscopy (Figure 4.6). A summary of the optical properties 
(excitation and emission maxima and quantum yield) for the compounds are reported 







Figure 4.3. Absorbance and emission spectra of A) XD-OH and XD-BGal, B) XD-Br 
and XDBr-BGal. Absorbance spectra recorded using a microplate reader with 10 µM 
probe in PBS + 5% DMSO. Fluorescence spectra recorded using a spectrofluorometer 
with 1 µM compounds in PBS + 5% DMSO. 
 























































































f is the absorption factor (f = 1-10-A, where A = absorbance)
 
F is the area under the emission curve, η is the refractive index of the solvents
 
ΦST is the quantum yield of the standard 
ST = standard, x = sample
 
Equation 3. Formula for the calculation of the quantum yield using the comparative method 





Table 4.3. Quantum yields (ΦF) were recorded with freshly prepared solutions (water 
+ 0.01% DMSO) compared to ICG. 
Code λex max (nm) λem max (nm) ΦF (620nm) 
XD-OH 680 714 0.118 
XD-BGal 596 661 0.003 
XD-Br 685 703 0.016 
XD-BrBGal 592 664 0.001 
 
There was little difference between the absorption and emission maxima for both sets 
of compounds, except for XD-Br having a broader absorbance extending over 800 nm 
compared to XD-OH (Figure 4.3). As expected, the galactose probe emitted very 
weakly in the 660 nm region, while the fluorophores emitted at 700-715 nm. The 
change in absorbance was also noticeable in their visual appearance in solution 
(Figure 4.4). Attaching galactose to XD-OH decreased the quantum yield by 40-fold, 
while XD-Br showed a 16-fold fluorescence quenching.  
 
The low quantum yield of XD-Br (ΦF = 0.016) suggested that the bromine heavily 
quenched the fluorescence of this molecule. It is surprising that Liu was able to use 
this molecule for fluorescent microscopy.126 This result meant the XD-Br compounds 





Figure 4.4: Colour change of XD-BGal and XD-BrBGal before and after β–gal 
enzymatic cleavage (1 µM, PBS). 
 
4.4.1. Effect of pH 
The intensity of fluorescence of XD-OH was dependent on the pH of the local 
environment due to the pH dependent equilibrium between the phenol and phenolate 
form of the fluorophore (Scheme 4.6). This is relevant as beta-galactosidase is a 
lysosomal enzyme and under the conditions of senescence lysosomal acidity can 
increase to a pH of 6.112 Therefore an ideal pro-fluorophore should have sufficient 
fluorescence intensity at this pH and this would ideally be pH independent. To 
understand the effect of pH on the probes photophysical properties, the absorbance 




Scheme 4.7. Equilibrium between the phenol and phenolate forms of the XD-OH 
fluorophore. 
 
Previously, Yuan found that the phenol group of XD-OH had a pKa of 5.6.
123 In our 
hands, with the change of pH from 4.5 to 7.4 the absorbance spectrum undergoes a 
red-shift from two maxima (600 and 660 nm) to a maxima at 690 nm, presumably due 
to the phenolate form of the dye (Figure 4.5A). With XD-BGal the phenolate cannot 
be formed due to O-alkylation with galactose, therefore the absorbance profiles of this 







Figure 4.8. HPLC stability study showing both the homogeneity of the initial sample 




To monitor the fluorescence generated by the probe in the presence of β-galactosidase, 
a microplate assay was used. XD-BGal was incubated with β-gal for 10 minutes giving 
a clear fluorescence increase with an emission maxima at 709 nm and reaching 
maximum intensity with 25 nM of enzyme (Figure 4.9). 
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Figure 4.9. Fluorescence spectra of XD-BGal (100 µM) after incubation with the 
indicated concentrations of recombinant β-Gal for 10 minutes as measured by 
microplate reader with excitation at 633 nm. Data from Philip Emanuel.  
 
The probe was characterised by steady-state kinetics with the fluorescence generated 
by incubating different concentrations of the probe (1 to 20 µM) with 5 nM β-Gal over 
30 minutes and the initial velocity calculated. Plots of initial reaction rate against 
concentration were generated and non-linear regression used to find the Michaelis 
constant (Km), according to the Michaelis-Menten equation (ν = Vmax [S]/Km + [S]). 
We measured a Km of 1.5 µM and a maximum rate, Vmax of 3.2 nM s
-1, showing that 
XD-BGal was efficiently cleaved by the enzyme. 
 
4.5.3. Competition with other endogenous glycans 
In the cellular environment numerous glycans are present and would decrease the 
fluorescence signal by competing with the fluorescent probe at the active site of 
enzymes. Two glycans were investigated, D-glucose which is a common component of 
cell culture media, and D-galactose which may be found after the hydrolysis of lactose 




















(100 nM), the fold change of fluorescence was 2-fold reduced as expected. However, 
glucose had no significant effect on the fluorescence increase, as expected as it is not 
a competitive inhibitor of β-gal. 
Figure 4.10. Quantification of fold change in fluorescence of XD-BGal in the 
presence of the sugars galactose and glucose. (n=3), Probe (50 µM), D-galactose 
(100 nM), D-glucose (100 nM). Data from Philip Emanuel. 
 
4.6. Epithelial cellular senescence 
Senescent cells with SA-βGal expression can be induced in culture by several different 
treatments including oxidative stress, cytokines and DNA damaging agents. In this 
work we required an in vitro model of epithelial senescence and this has previously 
been carried out by treating epithelial cells with bleomycin.127, 128  
 
Bleomycin was discovered in the 1960’s as a fungal natural product with antitumor 
activity and has been used as a chemotherapy drug.129, 130 Although its exact mode of 
action is still not fully understood, bleomycin is known to cause DNA strand breaks in 
the presence of Fe(II) and Cu(I) triggering the DNA damage response.130, 131 However, 

















































threatening,130 thus bleomycin has been used in lung injury models as its 
administration leads to pulmonary fibrosis.132  
 
A549 cells were used to represent the type II alveolar cells that have been seen to 
undergo senescence in pulmonary fibrosis. For this, the lung adenocarcinoma cell line 
A549 was treated with bleomycin sulfate for 24 hours to induce stress-induced 
senescence. Initially, β-galactosidase activity after bleomycin treatment was 
confirmed by the classic blue precipitation of the X-gal colorimetric stain, as well as 
changes in cell morphology to enlarged and flattened structures. A549 cells that were 
not treated were used as a control group and showed no X-gal staining. 
 
Figure 4.11. Bleomycin, an anti-cancer drug that can be used to trigger cellular 
senescence. 
 
The XD-BGal probe was used to fluorescently stain cells to see if the fluorescence 
was specific to senescent cells. By fluorescence microscopy, the senescent cells 
showed clear NIR fluorescence after 30 minutes staining (Figure 4.12B). Observation 
under higher magnification showed the fluorescence was intracellular and appeared to 




experimentally comparing the lysosomal accumulation of fluorophore at the regular 
lysosomal pH ~ 4.5 to pH 6. Future work would look at imaging after lysosomal 
alkalisation using bafilomycin A1, an inhibitor of VTP-ase that is responsible for 
inhibiting acidification of lysosomes. 
 
The use of A549 cells has some limitations as a model, mainly the concern that treating 
cancer cells which have abnormal proliferation with an anti-cancer drug does not 
replicate normal alveolar epithelium function. In addition it is not clear whether 
bleomycin itself increases βGal activity. However, the selectivity seen by the probe 
for senescence epithelial cells gave promise to investigating its use further. 
  
4.6.1. Fibrotic lung slice imaging 
A common functional ex vivo assay is to use tissue slices. The precision cut lung slice 
model is an ex vivo model for examining lung structure and function whereby lung 
tissues are inflated and cryosectioned on a microtome. It provides an ideal model for 
validating lung imaging agents since these slices can be maintained in cell media for a 
time. The ability to prepare murine and human tissue sections using this technique, 
giving optically thin and viable cells, has been demonstrated.  
 
Using the precision cut lung slice model with murine lung we tested whether our probe 
could detect beta-galactosidase activity as in vivo exposure of mice to bleomycin has 
been shown to generate SA-βGal activity. By confocal microscopy, a murine lung 
tissue slice was stained with the probe and imaged (Figure 4.13). A large proportion 





In conclusion, the application of XD-BGal in cellular models of senescence showed 
its feasibility for future studies in more advanced models. Each probe and fluorophore 
were characterised to understand their photophysical properties, stability and kinetics. 
XD-BGal showed selectivity for A549 cells that were treated with a chemotherapy 
agent (bleomycin) to cause SA-βGal expression. Initial imaging of murine lung slices 
showed that a number of cell types expressing galactosidase activity could be detected. 
In future, these positive staining cell types should be classified in more detail by 
immunohistochemical or other techniques. While the brominated analogue 
(XD-BrBGal) was not used for microscopy studies, in an attempt to understand the 
fluorescent properties of this probe the singlet oxygen quantum yield was calculated. 
 
4.7.1. Singlet oxygen generation 
The XD-Br probe had a low quantum yield (0.016) probably due to the presence of 
the bromide group. It is also known that fluorophores can generate singlet oxygen 
through the heavy atom effect, however the efficiency of singlet oxygen generation is 
often a trade-off with the fluorescence quantum yield.133 Common photosensitisers 
such as methylene blue (MB) and Chlorin E6 (Ce6) exhibit high singlet oxygen 
generating capacity (0.55 and 0.66, respectively), but MB has a low fluorescence 
quantum yield (0.02).133 It was suggested that XD-Br could be capable of generating 
singlet oxygen with a potential application as a photosensitiser.  
 
XD-BrBGal could be used to detect cells that express high levels of β-gal and act as 




Table 4.4. Properties of the fluorophore singlet oxygen generation capabilities were 
determine according to procedure by Lin.134 Samples of each fluorophore in oxygen-
bubbled methanol solutions were irradiated under a 650 nm LED lamp for 30 minutes. 




quantum yield (ΦF) 
Singlet oxygen 
quantum yield (ΦΔ) 
MB 668 0.02 0.55 
Cy5 640 N.D. 0.065 
XD-OH 680 0.118 0.062 
XD-Br 685 0.016 0.119 
XD-BrBGal 592 0.001 0.055 
 
XD-Br was capable of generating singlet oxygen and although the efficiency was low 
(compared to MB) it was similar to the efficiency of HiPorfin, a Chinese clinically 
approved PDT agent.134 Additionally, there was a 2.2-fold reduction in 1O2 generation 
when the galactosyl moiety was present, suggesting XD-BrBGal could be used as an 
activatable photosensitiser for killing cells. 
 
4.8. Further work 
Modifications to the fluorophore chemical structures were attempted to improve the 
solubility of the probes as they required dissolution in DMSO. However, these efforts 
were not successful during this project. Several analogues were proposed in order to 
improve on the properties of the dye structure. For example a sulfonate dye would 
have better solubility (Figure 4.14), but it was unclear whether this would make the 




Figure 4.14. Left: A hemicyanine fluorophore with a sulfonate group used to increase 
hydrophilicity. The clogP of SulfXD-OH was calculated as -0.19 (molinspiration). 
Right: HPLC chromatogram of the isolated SulfXD-OH fluorophore with detection at 
650 nm. The retention time (tR) of 4.1 min, compared to XD-OH which has a tR of 4.4 
min.  
 
A probe could be synthesised in three steps starting from the sulfonated Cy7 dye 
(Scheme 4.8). However, several unsuccessful attempts were made to attach the 
























Scheme 4.9. Proposed synthetic route to sulfonated XD-BGal analogue.  
 
An alternative structure involved a cleavable galactosyl moiety connected to a Cy7 
aminocyanine (Scheme 4.9), this would have ratiometric fluorescent properties based 
on the unique properties of aminocyanines.135 Following on from the synthesis of an 
esterase sensitive Cy7 dye, the galactose analogue was targeted (Scheme 4.10). with 
the reaction of the mixed carbonate (Gal-Bn-PNP) with the secondary aminocyanine 
(Bn-Cy7) (Scheme 4.10). However, the carbamate product could not be isolated and 




There are many potential ways of designing new beta-galactosidase Smartprobes. It 
has been previously shown that fluorophores can leach from the site of activation, 
leading to false positive results in regions without galactosidase activity. This could 
be solved by incorporating a group to covalently link the fluorophore XD-OH to 
proteins at the site of activation.122 
 
As well as optimising the probe, additional analysis in ex vivo precision cut lung slice 
models are needed to understand the labelling performance of XD-BGal, whether it is 
truly selective for lysosomal β-gal and the potential for application a clinical setting 
where other cells may activate the probe (e.g. macrophages).
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5. Conclusions and outlook 
5.1. Introduction 
The prospect of an optical biopsy to interrogate human lung diseases offers the 
potential to improve both the diagnosis and treatment of such diseases. Optical 
molecular imaging by endomicroscopy, in combination with SmartProbes, has been 
previously validated as a way of analysing lung pathologies in humans.15 The ability 
to extend this technology to other cell types was a key aim of this research.  
 
The innate immune system plays a major role in the body’s response to disease, more 
specifically, understanding the functions of macrophages is a major focus of 
biomedical research. For example, macrophages are known to respond to 
inflammatory stimuli through the release of various cytokines and chemokines, the 
phagocytosis of opsonized targets and cellular signalling. Macrophage activity in the 
lung has been associated with pathologies such as asthma, where alveolar macrophages 
produce higher IL-13 levels and impaired IL-12 production144, 145; in COPD where a 
bias towards M2 macrophages was reported37; and in IPF patients where CD163 is 
highly expressed by M2-like macrophages.146 
 
Folate receptors have been identified on macrophages in several inflammatory 
diseases such as rheumatoid arthritis, osteoarthritis and IPF. A previous study reported 
uptake of a folate conjugate by pulmonary macrophages in a rodent model of acute 




inflammation. As folate-based imaging conjugates accumulate in multiple different 
inflammatory diseases, investigating this type of conjugate would provide valuable 
information on the role of folate receptors in lung inflammation. Secondly, 
macrophage mannose receptors (MMR) are another target for lung macrophage 
imaging. In addition to work reporting mannose receptors on tumour-associated 
macrophages in lung cancers,78 Bazzan used MMR as a biomarker of M2 polarised 
macrophages in lung sections and this positively correlated with increased COPD 
severity.81 More recently, a variety of MMR avid peptides, glycopolymers and 
antibody fragments have emerged as methods of labelling MMR positive 
macrophages.85, 86 
 
Tissue remodelling is a feature of chronic airway diseases and can lead to the 
accumulation of senescent cells in tissues. The role of senescent cells expressing the 
senescence-associated beta-galactosidase enzyme has previously been investigated in 
alveolar epithelial cells exposed to cigarette smoke.108 The prospect of validating a 
fluorescent probe to detect this enzyme would help our understanding of the integrity 
of the epithelium in lung diseases such as fibrosis. 
 
Overall, the ability to image macrophage activity and epithelial cells in vivo would 
help give a better understanding of the role of these cells in the lung during disease. 
Thus, to gain an understanding of macrophage activity and alveolar epithelial integrity, 
a number of families of SmartProbes were synthesised and their abilities to selectively 





5.2. Conclusions and future experiments 
5.2.1. Folate receptor probes 
In Chapter 2, the folate receptor was utilised as a method for imaging macrophages. 
Initially a reported folic acid probe was synthesised, however optimisation of later 
probe structures was difficult using solution-phase chemistry due to the polarity of 
folic acid. This led to the development of a new solid-phase methodology (FolateTag) 
for the efficient construction of folate conjugates and provided a terminal amine for 
fluorophore conjugation. The FolateTag method allowed the synthesis of a spectrum 
of fluorescent Smartprobes that were evaluated for folate receptor imaging.  
 
With cancer cell cultures, these probes were able to identify folate receptor-alpha 
expressed on the cells surface and this was demonstrated to be a target-specific event 
through competition and control experiments measured by flow cytometry and 
confocal microscopy. With this data giving confidence that these probes bound to 
folate receptors, attempts were made to identify an in vitro model of folate receptor-
beta expressing macrophages. The Cy5-folate probe (probe 7 at 50 nM) could detect 
folate receptor-beta on monocyte-derived macrophages differentiated with monocyte 
colony stimulating factor (M-CSF), in contrast non-specific binding was seen by the 
non-expressing NR8383 alveolar macrophage cell line by flow cytometry. Imaging 
data showed that probe 7 was selective for M2 (M-CSF differentiated) over M1 
macrophages (granulocyte-macrophage colony-stimulating factor differentiated). This 
work supports the conclusion of work by Puig-Kröger that M-CSF stimulated 




conclusive in showing a lung macrophage population could be detected by these 
conjugates. 
 
In collaboration with another academic group interested in investigating the function 
of the folate receptor, the Cy5-folate probe was further validated with macrophages 
from the peritoneal cavity of aged mice, showing that folate receptor-beta (FRβ) could 
be detected by flow cytometry on 20 % of macrophages (gated on CD11b+/ F4/80high/ 
MHC class IIlow status). While the presence of FRβ+ macrophages in the peritoneal 
cavity has been reported previously,50 further work would be needed to determine the 
function of these cells, particularly in an inflammatory model. With the Phase II and 
III trials of the folate agent OTL38 in ovarian and lung cancer, the agent developed 
here would be interesting to develop further for diagnosis of diseases where folate 
receptor expressing macrophages are relevant.147  
 
5.2.2. Macrophage nanobody probe 
Fluorescently labelled nanobodies are an emerging imaging modality and an 
alternative to antibody imaging conjugates. In Chapter 3, this modality was explored 
for the optical imaging of macrophages with the aim of labelling a nanobody with a 
far-red fluorophore. After scouting for conjugation conditions using the model small 
protein lysozyme, the sulfoCy5 dye was successfully conjugated to a nanobody 
targeting the macrophage mannose receptor. The identity of the final conjugate was 





The labelled nanobody (Cy5-Nb) was progressed to in vitro assays with monocyte-
derived macrophages from healthy volunteers to show that the probe had high affinity 
and specificity to macrophages versus a panel of other common cells found in the lung: 
neutrophils, monocytes and control cancer cells. In the course of this work the probe 
showed intracellular labelling in macrophages suggesting that it had been actively 
processed by the cells. Despite attempting chemical blocking methods, we could not 
determine if this was a phagocytotic or endocytic mechanism. The probe showed 
benefit as a macrophage imaging agent as it labelled positively with ex vivo lavage 
samples from patients with chronic lung diseases (COPD and IPF patient samples). 
 
Future work with this probe would focus on testing it in a whole lung model to show 
that probe signal can be detected from labelled macrophages against other cells. In 
addition, studies would be needed to see if the nanobody causes an adverse 
immunogenic response when used in vivo. Given its applicability to macrophage 
imaging, this nanobody probe could see rapid advancement into preclinical models 
and represents the first fluorescent nanobody developed for macrophage imaging. 
While nanobodies are still in their infancy, the FDA approval of the nanobody 
Caplacizumab in 2019 gives confidence in the clinical progression of nanobody 
imaging agents.94  
 
5.2.3. Beta-galactosidase probes 
In Chapter 4, activity-sensing fluorophores were developed for detecting senescent 
epithelial cells in the lung. While a number of existing probes are reported to visualise 




models, or their fluorescent properties would not be ideal for use in vivo. A near-
infrared (NIR) galactosidase probe (XD-BGal) was evaluated for detecting senescent 
cells that expressed senescence-associated beta-galactosidase (SA-βGal) enzyme. XD-
BGal was successfully enzymatically activated by beta-galactosidase enzyme in a 
HPLC-based assay and confirmation that this turned-on its fluorescence was detected 
by spectroscopy. In vitro senescent cell assays were carried out with A549 cancer cells 
that were induced to be senescent with bleomycin and bright intracellular fluorescence 
was detected specifically in the senescent group and only weak fluorescence in the 
control group of untreated, healthy cells. An animal model of bleomycin induced 
senescence was carried out and ex vivo examination of murine lung tissue slices was 
used to validate the probe. By microscopy, a large number of cells stained positively 
for beta-galactosidase, although in these preliminary results it was not confirmed that 
these cells were all senescent epithelial cells, and some might be macrophages. Further 
validation of lung slices with immunohistochemistry would be needed to show that the 
probes activation was specific to senescent cells.  
 
An analogue of the galactosidase probe was developed called XD-BrBGal, but the 
fluorophore after cleavage had a poorer fluorescent quantum yield (ΦF = 0.016) than 
the non-brominated fluorophore XD-OH, limiting its uses for fluorescence imaging. 
However, a solution-based fluorescence assay for determining singlet oxygen 
generation showed the fluorophore (XD-Br) was able to generate singlet oxygen (ΦΔ 
= 0.12). With further work, it was hypothesised that this probe could find an 
application as an activatable photosensitiser probe for specifically targeting beta-





While the ability to image senescence-associated beta-galactosidase positive cells with 
a SmartProbe was carried out in a number of assays, further experiments would be 
needed to show that senescent cells can be imaged in the human lung with optical 
endomicroscopy. This work should be placed in the context of other targeting 
techniques for senescence such as the work by Muñoz-Espín who developed a 
therapeutic delivery system directed to senescent cells based on their high β-
galactosidase activity and this showed the ability to treat pulmonary fibrosis in mice.148 
This gives hope that a SmartProbe approach to imaging senescent cells could be 
possible in preclinical models. 
 
5.3. Outlook  
Together, these sets of probes advance the collection of imaging agents for examining 
inflammatory processes in the lung, while greatly encouraging their use with in vivo 
models of lung inflammation. New ways to validate these probes in more lung relevant 
models were explored, such as using patient lung lavages in ex vivo assays and tissue 
precision cut lung slices. While lung slices were taken from an animal for this work, 
similar experiments could be performed with tissue from human donors to give more 
information on human immune responses.  
 
In vivo optical imaging is still an emerging field with many challenges ahead. A key 
problem is that the tissue penetration depth for molecular imaging is limited by light 
scattering, yet techniques such as fluorescence guided surgery and optical fibre 




approved targeted imaging agents to use with molecular imaging systems. For more 
widespread use of optical molecular imaging, further imaging agents will need to be 
taken into clinical trials. From this work, there are several avenues of future work to 
advance each Smartprobe towards clinical use. The use of Smartprobes in vivo firstly 
requires an understanding of the biocompatibility and toxicology of each probe. 
Similar work was carried out in the development of Smartprobes in clinical trials 
presently; for example, the c-Met targeting probe GE-13719 and the folate receptor 
probe OTL-38.47 While each probe showed target specificity, the ability to detect their 
target biomarkers of inflammation in a whole lung model would need to be confirmed. 
Future work should also include the development of the physiochemical properties of 
each probe as needed for a biocompatible formulation. 
 
Ongoing developments in the field of optical imaging include the validation of new 
probe targets, new imaging systems and better designed SmartProbes requiring low 
background signals.149, 150 Future opportunities to develop the field of optical 
molecular imaging from this work can be imagined. While this work focused on 
cellular identification by targeting inflammatory cells, simple modifications to the 
structure of these probes could allow them to be used in alternative modalities of 
optical imaging. These include the development of SmartProbes using photosensitisers 
for photodynamic therapy, Raman tags for stimulated Raman scattering, or labels that 





6.1. General section: Chemistry 
All solvents and reagents were obtained from commercial suppliers and used without 
further purification, unless otherwise stated. Evaporation of solvents was performed at 
reduced pressure, using a Büchi rotary evaporator. All solution phase reactions were 
stirred magnetically unless otherwise stated and followed to completion by thin layer 
chromatography (TLC), where appropriate using TLC aluminium sheets coated with 
silica gel 60 F254 plates (Merck) or RP-18 silica gel (Macherey Nagel). TLC 
visualisation was performed using short wave UV light (254 nm) and/or TLC staining 
solutions where stated.  
 
Reactions involving moisture sensitive reagents were performed under nitrogen and 
reactions involving light sensitive compounds were kept under aluminium foil at all 
times. Compounds were dried under vacuum at 40oC in a Heraeus vacuum oven. 
 
Fourier-transform infrared spectroscopy were recorded on a Bruker Tensor 27 
spectrophotometer with Specac single reflection diamond attenuated total reflexion 
(ATR) Golden Gate accessory. Fluorescence spectra were recorded on a Horiba 
FluoroMax fluorospectrometer, using 1 cm path length with fused silica cuvettes. 
UV/Visible absorbance spectra were recorded on a BioTek SynergyHT or Synergy H1 
plate reader in well plates, or Shimadzu UV1800 spectrophotometer using a 1 cm path 





1H and 13C NMR spectroscopy were recorded on automated Bruker AV400 or 
AV500 spectrometer in the deuterated solvents indicated at 298 K. Chemical shifts are 
reported on the  scale in ppm. Resonances were characterised as singlet (s), broad 
singlet (bs), doublet (d), doublet of doublet (dd), triplet (t) or multiplet (m) with 
coupling constants given in hertz (Hz). Data was processed using the MestReNova 
software version 10 (Mestrelab Research S.L.) 
 
Microwave heating was carried out by irradiating the reaction mixture in a Biotage 
Initiator at 2.45 GHz. Experiments were carried out in Biotage sealed tubes. 
Microwave irradiation was conducted at a defined temperature and time, with pressure 
and power monitored by the systems software. 
 
Reverse-phase high-performance liquid chromatography (RP–HPLC) 
Analytical HPLC was performed on an Agilent Technologies 1100 modular HPLC 
system coupled to a Polymer Lab 1000 Evaporative Light Scattering Detector (ELSD), 
with simultaneous detection at 220, 254, 260, 282 and 495, 650 nm. Column: 
Phenomenex Kinetex® 5µm XB-C18 100 Å, LC Column (50 x 4.6 mm), with a flow 
rate of 1 mL/min. All solvents used were HPLC grade. 
A: MeCN + 0.1% formic acid 
B: H2O + 0.1% formic acid  
Method 1: 5 to 95 % A in B over 6 min; Isocratic for 3 min; 95 % to 5% A over 1 




Method 2 (5PCTMIN): 5% to 95 % A in B over 18 min; Isocratic for 3 min; 95% to 
5% A over 1 min; 2 min isocratic. 
 
Preparative RP–HPLC (system 1) was performed on an Agilent Technologies 1100 
modular HPLC system equipped with a Agilent Zorbax Eclipse® 5µm XDB-C18 
column (250 x 10 mm) with a flow rate of 2.0 mL/min.  
Preparative RP–HPLC (system 2) was performed on an Agilent Technologies 1100 
modular HPLC system equipped with a Phenomenex Kinetex Axia 5µm XDB-C18 
column (150 x 21.2 mm) with a flow rate of 10.0 mL/min.  
Elution was using one of the following methods. 
Method 1: eluting with A in B, with a gradient of 5 to 95% B over 18 min and an 
initial isocratic period of 5 min and a final isocratic period of 2 min. 
Method 2: eluting with C in D, with a gradient of 5 to 95% D over 22 min and an 
initial isocratic period of 7 min and a final isocratic period of 2 min.  
Method 3: eluting with E in F, with a gradient of 5 to 95% F over 18 min and an initial 
isocratic period of 5 min and a final isocratic period of 2 min.  
A: H2O + 0.1% formic acid  
B: MeCN + 0.1% formic acid  
C: H2O + 0.1% trifluoroacetic acid 
D: MeCN + 0.1% trifluoroacetic acid  
E: 10mM ammonium bicarbonate H2O solution 






Electrospray ionization mass spectrometry (ESI–MS) analyses were carried out on an 
Agilent Technologies LC/MSD Series 1100 quadrupole mass spectrometer (QMS) in 
the ESI mode. Column: Phenomenex Kinetex® 5µm XB-C18 100 Å, LC Column (50 
x 4.6 mm), with a flow rate of 1 mL/min. 
 
High Resolution Mass Spectra (HRMS) were performed on a Bruker microTOF2 
spectrometer by direct infusion. MALDI-TOF mass spectra were obtained with a 
Bruker UltrafleXtreme MALDI TOF/TOF instrument and analysed with the Bruker 
Daltonics flexAnalysis software. 
 
6.2. General section: Biology 
The following reagents and materials were purchased; DMEM cell culture media 
(Gibco, 21969-035), L-Glutamine 200mM (Gibco 25030081), Foetal Bovine Serum 
(Gibco 10500064), Penicillin-Streptomycin 10,000 U/mL (Gibco 15140122), 
Amphotericin B (Gibco 15290018).  
Phosphate buffered saline (PBS) buffer was prepared as follows: 0.01 M phosphate 
buffer, 2.7 mM potassium chloride and 0.137 M sodium chloride, pH 7.4, at 25 °C. 
 
Flow cytometry analysis was carried out on a BD FACScan or FACS Canto II 
cytometer. Data was analysed using FlowJo software v10. Protein gels were imaged 
on a BioRad Laboratories Molecular Imager and processed with BioRad Laboratories 
Image Lab Software 3.0. Microplate reader assays (absorbance, fluorescence and 
luminescence) were performed on a BioTek Synergy H1 or SynergyHT plate reader 




of ImageJ.140 UV-Vis measurements of proteins were made using a Nanodrop 1000 
spectrometer with Nanodrop 100 software version 3.8.1 (ThermoScientific). Cell 
counting and viability testing was performed with Vial1 cartridges on a Nucleocounter 
(Chemometec). 
 
Biological data was analysed with GraphPad Prism (v5) software and generally results 
are presented as mean ± standard error of the mean (SEM).  
 
Whole blood from healthy volunteers was collected according to Research Ethics 
Committee approval under the AMREC 15-HV-013 project at the Centre for 
Inflammation Research, University of Edinburgh. Healthy volunteers provided written 









Compound 12 was prepared according to a reported procedure.58 In a round-bottomed 
flask was dissolved folic acid (640 mg, 1 eq.) in DMSO (25 mL). After dissolution 
was complete (about 30 minutes with mild heating), N-hydroxysuccinimide (NHS, 
308 mg, 2 eq.) and dicyclohexylcarbodiimide (DCC, 552 mg, 2 eq.) were added 
successively. The reaction mixture was stirred for 18 hours at room temperature, after 
which the white urea precipitate was filtered off. Triethylamine (TEA, 0.376 mL, 2 
eq.) was added to the filtrate, followed by N-Boc-ethylenediamine (429 mg, 2 eq.) 
dissolved in DMSO (5 mL). The mixture was again stirred overnight before a mixture 
of 20% acetone in diethyl ether was added. The thin yellow precipitate was carefully 
centrifuged and washed four times with acetone and two times with diethyl ether and 
dried under vacuum (770 mg, 91%). Data in agreement with the literature.58 MS (ESI) 
calculated for C26H33N9O7 [M+H]
+ m/z 584.3. Found 584.3 (100%). 1H NMR (500 
MHz, DMSO-d6) δ 8.64 (s, 1H), 8.18 – 7.75 (m, 2H), 7.73 – 7.56 (m, 2H), 7.00 – 6.74 
(m, 3H), 6.69 – 6.57 (m, 2H), 4.48 (br, 2H), 4.28 (m, 1H), 3.12 – 2.88 (m, 4H), 2.33 – 
1.79 (m, 4H), 1.35 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 174.14, 173.96, 171.87, 
171.83, 171.73, 166.13, 161.03, 155.56, 153.86, 150.71, 148.54, 129.06, 128.89, 







Compound 13 was prepared according to a reported procedure.58 Compound 12 (100 
mg, 0.17 mmol), was dissolved in trifluoroacetic acid (0.66 mL) and stirred for two 
hours at room temperature. The solvent was removed under vacuum, adding DCM to 
aid TFA removal. The resulting residue was dissolved in the minimal amount of dry 
DMF, triethylamine (300 µL) was added to give a yellow precipitate. This was filtered, 
centrifuged and washed four times with acetone and twice with diethyl ether. Resulting 
in the final compound as a yellow powder (66 mg, 80%). Data in agreement with the 
literature.58 1H NMR (500 MHz, DMSO-d6) δ 8.67 – 8.59 (m, 1H), 7.84 – 7.73 (m, 
1H), 7.72 – 7.54 (m, 2H,), 7.00 – 6.72 (m, 3H), 6.69 – 6.57 (m, 2H), 4.48 (br, 2H), 
4.36 – 4.01 (m, 1H), 2.88 – 2.74 (m, 2H), 2.30 – 2.12 (m, 2H), 2.06 – 1.96 (m, 2H). 
CH2 obscured by H2O peak 
 
FITC Folate (1) 
 
FITC Folate was prepared according to a reported procedure.41 To a solution of 




fluorescein isothiocyanate (FITC, 20 mg, 0.051 mmol) and DIPEA (13 µL, 0.075 
mmol). The reaction was stirred under nitrogen for 4 hr in the dark. The product was 
precipitated by adding water and sonicating. The filtrate was collected and washed 
with diethyl ether. The pure product was obtained by prep-HPLC purification as an 
orange solid (4 mg, 18 %). All data was in agreement with the literature.41 MS 
(MALDI-TOF matrix: CHCA): calculated for C42H36N10O10S [M+H]
+ m/z 873.2. 
Found 873.3 (100%). HRMS (ESI) m/z: [M+H]+ calcd for C42H36N10O10S 873.2409. 
Found 873.2394. 1H NMR (500 MHz, DMSO-d6) δ 10.18 (s, 1H), 8.67 – 8.58 (m, 1H), 
8.38 – 8.26 (m, 1H), 8.24 – 8.17 (m, 1H), 7.90 – 7.82 (m, 1H), 7.75 – 7.58 (m, 2H), 
7.21 – 7.10 (m, 1H), 6.72 – 6.60 (m, 2H), 6.62 – 6.50 (m, 6H), 4.52 – 4.42 (m, 2H), 
4.40 – 4.20 (m, 1H), 3.56 (s, 2H), 3.34 – 3.23 (m, 2H), 2.29 – 2.14 (m, 2H), 2.13 – 
1.85 (m, 2H). 
 
Potassium 2,3,3-trimethyl-3H-indole-5-sulfonate (14) 
 
Compound 14 was prepared according to a reported procedure.136 4-
hydrazinobenzenesulfonic acid (5 g, 26.6 mmol) and 3-methylbutan-2-one (6.86 g, 
79.8 mmol) were dissolved in acetic acid (15 mL) and stirred at reflux for 3 hours. The 
solvent was removed under vacuum. The residue was then dissolved in methanol and 
stirred with a saturated solution of potassium hydroxide (1.5 g) in 2-propanol (50 mL). 
The solution turned yellow and the potassium salt was collected by filtration, washing 
with diethyl ether and the solid dried under vacuum overnight yielding a pale-yellow 




HPLC (Method 1) tR = 1.22 min. Purity 100% (ELSD). MS (ESI): calculated for 
C11H12KNO3S [M+H]
+ m/z 278.0. Found 278.1 (100%). 1H NMR (500 MHz, DMSO-
d6) δ 7.62 (d, J = 1.6 Hz, 1H), 7.53 (dd, J = 7.9, 1.7 Hz, 1H), 7.33 (d, J = 7.9 Hz, 1H), 




Compound 15 was prepared according to a reported procedure.136 Potassium 2,3,3-
trimethyl-3H-indole-5-sulfonate 14 (250 mg, 0.90 mmol), 6-bromohexanoic acid (176 
mg, 0.90 mmol) were dissolved in toluene (2 mL) and refluxed for 24 hours. The 
reaction mixture was cooled to ambient temperature and further toluene added. The 
thick precipitate was filtered and washed with toluene and diethyl ether. Dried under 
vacuum to give a brown solid (251 mg, 79%). All data was in agreement with the 
literature.136 HPLC (Method 1) tR = 2.33 min. Purity 90% (ELSD). MS (ESI): 
calculated for C17H22NO5S [M-H]
- m/z 352.1. Found 352.1 (100%). 1H NMR (500 
MHz, DMSO-d6) δ 8.03 (s, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.83 (dd, J = 8.4, 1.6 Hz, 
1H), 4.44 (t, J = 7.7 Hz, 2H), 2.83 (s, 3H), 2.23 (t, J = 7.2 Hz, 2H), 1.87 – 1.80 (m, 
2H), 1.55 (m, 8H), 1.45 – 1.37 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δ 197.3, 









Compound 16 was prepared according to a reported procedure.137 1-(5-
carboxylpentyl)-2,3,3-trimethylindolium-5-sulfonate 15 (250 mg, 0.57 mmol), 
malonaldehyde bis(phenylimine) hydrochloride (204 mg, 0.79 mmol) were dissolved 
in a 1:3 solution of acetic acid (0.8 mL) and acetic anhydride (2.5 mL). The reaction 
was heated to reflux and monitored by LC-MS until starting indolenine was consumed 
(~1 hour). The reaction was cooled to room temperature, the solvent was evaporated 
and a solid precipitated by addition of ethyl acetate. The solution was filtered and 
washed several times with ethyl acetate and finally with diethyl ether. After drying 
under vacuum the brown solid (271 mg, 90%) was used directly without purification. 
All data was in agreement with the literature.137 MS (ESI): calculated for C28H33N2O6S 
[M+H]+ m/z 525.2. Found 525.2 (100%). HPLC (Method 1) tR = 4.57 min. Purity 88% 
(ELSD). 1H NMR (500 MHz, DMSO-d6) δ 8.93 (d, J = 13.3 Hz, 1H), 8.59 (m, 1H), 
7.97 (m, 1H), 7.77 – 7.42 (m, 7H), 6.88 (dd, J = 15.0, 3.4 Hz, 1H), 5.58 – 5.50 (m, 
1H), 4.31 – 4.22 (m, 2H), 2.15 (t, J = 7.3 Hz, 2H), 1.91 (s, 3H), 1.71 (d, J = 5.5 Hz, 





Dipotassium 2,3-dimethyl-1,3-di(4-sulfonatobutyl)-3H-indolium-5-sulfonate (17) 
 





Cy5** was prepared according to a reported procedure.137 Indolenine 
phenylacetoamide 3 (800 mg, 1.52 mmol) and trisulfonated indolenine 4 (1.2 g, 2.41 
mmol) were dissolved in a solution of acetic acid and acetic anhydride (3:1 v/v, 21 
mL) with gentle heating. Potassium acetate (297 mg, 3.04 mmol) in acetic acid (5 mL) 
was added and the reaction heated to 110C for 30 minutes. Reaction conversion was 
determined by HPLC, after 30 minutes starting material 3 was remaining so the 




material remained. The reaction mixture was concentrated under vacuum to a viscous 
solution and ethyl acetate was added before stirring for 1 hour. The product was 
filtered under nitrogen, washed with ethyl acetate and collected as a dark blue powder. 
The crude product was suspended in water and stirred for 1 hour and the aqueous layer 
freeze-dried. Crude mass = 2.65 g. 
500 mg batches of crude material, dissolved in 1 M TFA (pH~2), were purified by 
Biotage flash chromatography (SNAP Ultra C18 30g column, up to 3% loading 
capacity) using gradient of 5% ACN in H2O to 35 % ACN in H2O (both with 0.1% 
TFA additive). Product fractions were lyophilised to yield a blue tinted powder. All 
data was in agreement with the literature.137 λex = 656 nm, λem = 670 nm (PBS). HPLC 
(Method 1) tR = 4.66 min. Purity 100% (ELSD). HRMS (ESI) m/z: calc for 
C38H50N2O14S4 [M+H]
+ 887.2218. Found 887.2258. 1H NMR (500 MHz, DMSO-d6) 
δ 8.43 – 8.28 (m, 2H), 7.80 (d, J = 1.7 Hz, 1H), 7.77 (d, J = 1.6 Hz, 1H), 7.63 (dt, J = 
8.2, 1.7 Hz, 2H), 7.35 (d, J = 8.3 Hz, 1H), 7.31 (d, J = 8.3 Hz, 1H), 6.60 (t, J = 12.3 
Hz, 1H), 6.41 (d, J = 13.8 Hz, 1H), 6.30 (d, J = 13.8 Hz, 1H), 2.44 – 2.22 (m, 4H), 
2.20 (t, J = 7.2 Hz, 2H), 1.80 – 1.67 (m, 6H), 1.69 (d, 6H) 1.66 (s, 3H), 1.55 (h, J = 
8.1, 7.3 Hz, 2H), 1.49 – 1.32 (m, 4H), 0.90 – 0.44 (m, 2H). 13C NMR (126 MHz, 
DMSO) δ 174.3, 172.9, 171.5, 153.6, 145.1, 142.8, 142.0, 140.5, 138.7, 126.2, 126.0, 
119.9, 119.7, 110.1, 104.1, 103.6, 53.3, 51.1, 50.6, 48.9, 43.4, 33.5, 27.2, 27.2, 27.1, 
26.6, 25.9, 25.6, 24.8, 24.2, 23.4, 22.3. 
 





N,N,N′,N′-Tetramethyl-O-(N-succinimidyl)uronium tetrafluoroborate (TSTU, 0.049 
mmol), DIPEA (8 µL) in DMF (0.5 mL), after one minute Cy5** (10 mg, 0.011 mmol) 
in DMF (0.5 mL) was added and the reaction shaken for 1 hour. Conversion to the 
NHS ester was monitored by HPLC. Ethylenediamine folate 2 was dissolved DMF 
(0.5 mL): NMP (0.1 mL), added to the NHS ester and shaken for 2 hours. Diisopropyl 
ether (DIPE) was added to the reaction mixture to form a solid and the yellow 
supernatant removed, further centrifuged and washed with DIPE three times. The 
green solid was purified by prep HPLC to yield the compound as the ammonium salt.  
MALDI-TOF (matrix: CHCA), calculated for C59H73N11O18S4 [M+H]
+ m/z 1352.4. 
Found 1352.6. HRMS (ESI) m/z: calc for C59H73N11O18S4 [M+Na]
+ 1374.3910. Found 
1374.1233. 
Poor solubility in deuterated NMR solvents prevented 1H NMR data being acquired. 
 
General procedures for the solid phase synthesis of folate probes 
To the Fmoc-amino acid (4 eq) in DMF (0.10 M), Oxyma (4 eq) was added and 
allowed to stir for 5 min. DIC (4 eq) was added and stirred for a further 5 min. The 




1 eq) pre-swelled in DCM and the reaction mixture was shaken for 2 h at room 
temperature. The resin was isolated by filtration, washed with DMF (3 × 10 mL), DCM 
(3 × 10 mL), and MeOH (3 × 10 mL). Coupling reactions were monitored by the 
ninhydrin test. Folic acid was coupled by reacting folic acid-NHS (prepared as 
described previously)58 in DMSO:NMP (1:1) with 1% DIPEA. The reaction mixture 
was shaken overnight and repeated if not deemed complete by HPLC. 
Fmoc deprotection was carried out by suspending the resin (0.20 g) in 20% piperidine 
in DMF (2 mL) and shaken for 5 min. The resin was filtered and a fresh solution of 
20% piperidine in DMF (2 mL) was added and shaken for 15 min. The resin was then 
filtered and washed with DMF (3 x 10 mL), DCM (3 x 10 mL) and DMF (3 × 10 mL). 
 
Dye couplings were carried out by the following method. The dde protecting group 
was removed with freshly prepared 2 % hydrazine in DMF solution (5x1 min, then 10 
min). The resin was filtered and washed with DMF (3 x 10 mL), DCM (3 x 10 mL) 
and DMF (3 × 10 mL) and the activated dye-NHS ester, DIPEA (170 μL) was added 
in DMF (0.1 M). The reaction mixture was shaken for a minimum of 3h at room 
temperature. The resin was drained and washed with DMF (3 × 10 mL), DCM (3 × 10 
mL), and MeOH (3 × 10 mL). 
TFA cleavage for Rink Amide resin was carried out by treating the resin with the 
cleavage cocktail TFA/TIS/H2O (95:2.5:2.5) (20 mL per gram of resin) and the 
mixture was shaken for 2-3h. The solution was drained and the resin was washed twice 
with TFA. The combined filtrates were evaporated until the minimal amount of solvent 
remained and this was added dropwise to a slowly stirring solution of cold ether (10-




and washed with cold ether three times, isolated and dried under vacuum. Purification 
of the probes was performed by RP-HPLC. HPLC method: 95% 10 mM NH4HCO3 
isocratic for 2 min; 5 to 95 % ACN in 10 mM NH4HCO3 over 7 min; Isocratic for 3 
min; 95 % to 5% 10 mM NH4HCO3 over 1 min. Characterisation was performed by 
MALDI-TOF and RP-HPLC. 
In general, the poor solubility of folate probes in deuterated NMR solvents and limited 







DMF was used to entirely remove the acetyl protecting groups on fluorescein. The 
crude product was cleaved from the resin and purified by RP-HPLC. 
HPLC (Method 1) tR = 5.5 min. Purity 85% (495 nm). HRMS (MALDI) m/z: calc for 
C52H53N11O15 [M+H]
+ 1072.3805. Found 1072.3848. 
 
NBD folate (6)  
 
The dye coupling procedure was carried out following the general procedure. NBD-Cl 
(3 equiv.) was coupled with the resin for 2h at room temperature. The crude product 
was cleaved from the resin and purified by RP-HPLC. 
HPLC (Method 1) tR = 5.9 min. Purity 100% (650 nm). MALDI: found [M+Na]
+ 
899.2, [M+Na+NH4]
+ 915.1, expected [M+Na]+ 899.3. HRMS (MALDI) m/z: calc for 
C37H44N14O12 [M+Na]
+ 899.3155. Found 899.3116. 
 





The dye coupling procedure was carried out following the general procedure, 2.5 
equiv. of Cy5**-NHS was reacted with the resin overnight at room temperature. The 
crude product was cleaved from the resin and purified by RP-HPLC. 
HPLC (Method 1) tR = 5.6 min. Purity 96 % (650 nm). MS (ESI): calculated for 
C69H90N13O22S4 [½M+Na]
+ m/z 812.4. Found [½M+Na]+= 812.4 (100%). HRMS 
(MALDI) m/z: calcd for C69H90N13O22S4 [½M+Na]
+ 812.2420. Found 812.4059. 
 
Benzothiophene enol ether (10) 
 
Compound 8 was prepared according to a reported procedure.139 1-benzothiophen-
3(2H)-one 1,1-dioxide (600 mg, 3.3 mmol) was added to a microwave vial with 
1,1,3,3-tetramethoxypropane (2.7 mL, 16.5 mmol), followed by the addition of 
trifluoroacetic acid (25 μL, 0.33 mmol). The vial was capped and heated to 150 °C for 




hexane/Et2O (3:1). The product was dried under vacuum and obtained as an orange 
solid (600 mg, 73%). Data in agreement with the literature.139 1H NMR (400 MHz, 
Chloroform-d) δ 8.09 – 8.01 (m, 1H), 7.98 (dq, J = 7.7, 0.9 Hz, 1H), 7.86 (tdd, J = 7.6, 
3.0, 1.3 Hz, 1H), 7.78 (ddd, J = 7.5, 6.8, 1.1 Hz, 1H), 7.71 – 7.63 (m, 1H), 7.45 (d, J 
= 11.9 Hz, 1H), 6.46 (dd, J = 12.8, 11.9 Hz, 1H), 3.96 (s, 3H). 13C NMR (126 MHz, 





MerocySO was prepared according to a reported procedure.139 1-(5-carboxypentyl)-
2,3,3-trimethyl-3H-indolium-5-sulfonate (184 mg, 0.52 mmol), sodium acetate (43 
mg, 0.52 mmol), and benzothiophene enol ether (100 mg, 0.40 mmol) were added to 
a microwave vial and suspended in 1:1 MeOH/CH2Cl2 (1 mL). The vial was capped 
and heated to 75°C for 30 min. The reaction mixture was cooled and concentrated, 
then purified by preparative HPLC (system 2). The product was obtained as a dark 
purple solid (29 mg, 14 %). HPLC (Method 1) tR = 4.5 min, Purity 100% (ELSD). MS 
(ESI): calculated for C28H29NO8S2 [M+H]
+ m/z 572.1. Found 572.1 [M+H]+ (100%). 
1H NMR (400 MHz, Methanol-d4) δ 8.00 (d, J = 7.4 Hz, 1H), 7.94 (d, J = 7.4 Hz, 1H), 
7.83 – 7.67 (m, 4H), 7.34 – 7.26 (m, 2H), 7.11 (t, J = 7.5 Hz, 1H), 6.92 (d, J = 7.9 Hz, 




6H). DEPT-135 13C NMR (126 MHz, MeOD) δ 156.4, 135.9, 134.9, 134.9, 127.9, 
124.5, 121.4, 121.2, 110.6, 102.7, 44.6, 34.6, 28.2, 27.9, 27.4, 25.8. 
 
 
MerocySO folate (9) 
 
The dye coupling procedure was carried out following the general procedure, with 1.4 
equiv. merocyanine SO-NHS was reacted with the resin overnight at room 
temperature. The crude product was cleaved from the resin and purified by RP-HPLC. 
HPLC (Method 1) tR = 6.5 min. Purity = >90% (280, 600 nm). HRMS (MALDI) m/z: 
calcd for C69H90N13O22S4 [M+Na+K]
+ 1327.3925. Found 1327.3712. 
 
6.3.2. Biological studies 
Materials 
The following reagents and materials were purchased; RPMI-1640 media (Gibco, 
 21875034), RPMI-1640 media without folic acid (Gibco, 27016021), M-CSF 
(R&D Systems, 215-GM), M-CSF (R&D Systems, 216-MC), CD14 microbeads for 




(Thermo-Fisher, PA5-45768), folic acid (Sigma, Biochemical grade F8758), 7-AAD 
(eBioscience, 00-6993-50), CellMask DeepRed (Invitrogen, C10046). Hoechst 33342 
(Invitrogen, H3570) and Calcein AM (Invitrogen, C-3100). LPS from E.coli. (Sigma 
Aldrich, L4391), rat IFN-γ (R&D systems, 585-IF),  Hoechst 33258 (Invitrogen, 
H3569), Ham’s F12K medium (Gibco, 21127022), mouse anti-rat CD32 (BD 
Biosciences, 550270, clone D34-485), PE labelled mouse FR-β (Biolegend, 391703, 
clone 94b), mouse IgG1 isotype control (Biolegend, 400112, clone MOPC-21), RIPA 
buffer (Sigma, R0278), EDTA-free proteinase inhibitor cocktail (Sigma, P1860), 
HRP-labelled goat anti-rabbit IgG secondary antibody (ProteinSimple, 040-656), 
CellTiter Glo 2.0 assay kit (Promega, G9242), Pierce LDH Cytotoxicity Assay Kit 
(Invitrogen, 88954). 
 
The KB cell line was obtained from ATCC (CCL17), A549 cells were donated by 
Emma Scholefield (CIR), NR8383 macrophage cells were obtained from the internal 
GSK cell biobank. Murine peritoneal macrophages were obtained by Pieter Louwe 
(CIR). 
 
Cancer cell culture 
KB and A549 cell lines were cultured in RPMI-1640 media supplemented with 10% 
fetal bovine serum (FBS), 1% L-glutamine and antibiotics (penicillin/streptomycin, 
100 U/mL). Cells were cultured at 37 oC in a 5 % CO2 atmosphere in a HeraCell 
incubator. Cells were harvested with trypsin/EDTA (0.25 % trypsin, 1 mM EDTA) 




folate conjugates, cells were cultured in folate-free RPMI-1640 medium (FF-RPMI) 
for at least 1 week prior.  
 
Live cell confocal microscopy 
KB or A549 cells were plated in ibidi μ-slide 8 well chamber slides (5 x 104 cells/ mL, 
300 μL/well) and cultured for 24 h. Media was removed and cells were treated with 
the counterstains Hoechst 33342 (1 μg/mL) and/or CellMask DeepRed (5 μg/mL), 
according to manufacturer’s instructions.  After incubation, cells were rinsed with PBS 
and incubated with the folate probe (in FF-RPMI media) for 15 min at 37 oC. The 
following concentrations of each probe were used: 1: 0.5 μM, 3: 1 μM, 5: 1 μM, 6: 1 
μM, 7: 0.5 μM, 9: 1 μM. 
After staining cells were rinsed with PBS once and fresh FF-RPMI media added. 
Confocal imaging was carried out under environmental control at 37 oC (5% CO2 
atmosphere) with a Leica SP5 microscope (settings: resolution 1024x1024 pixels; x40 
oil or x63 oil objectives; laser lines 405 nm, 488 nm, 633 nm; detection at 435-460 nm 
(for Hoechst), 500-550 nm (for fluorescein), 640-750 (for Cy5). Images were extracted 
using the Leica LAS AF software and analysed with the Fiji distribution of ImageJ.140 
 
Flow cytometry 
KB or A549 cells were plated in 24-well plates (1 x 105 cells per well) and cultured 
for 24 h. Media was removed and cells were treated with the folate conjugate (100 nM) 
in FF-RPMI for 30 min at 37 oC, or left untreated as a control. After incubation cells 
were washed with PBS, harvested with trypsin/EDTA and resuspended in fresh FF-




cytometer with CellQuest software. Optical settings: Excitation at 488 nm and 
emission filtered at 525/20 nm (FITC) for probes 1, 5 and 6, or excitation at 633 nm 
and emission filtered 666/27 nm (Cy5) for probes 3 and 7.  
 
For competitive studies the same procedure was used, except cells were first incubated 
with 1000-fold excess of folic acid (100 mM) for 15 min at 37 oC to saturated any 
available folate receptors. The solution was removed and subsequently the folate 
conjugate (100 nM) in FF-RPMI was added for 15 min at 37 oC. After incubation cells 
were washed with PBS, harvested with trypsin/EDTA and resuspended in fresh FF-
RPMI media. Flow cytometry was then performed. 
 
Relative binding affinities were calculated from flow cytometry data of serial dilutions 
of probes 1, 3, 5, 7 (0, 2, 5, 10, 25, 50, 100 nM) to KB cells using the same procedure. 
Non-linear regression curves were fitted to the MFI values of each probe using Prism. 
The KD was determined from the concentration of ligand at which half of the receptors 
are occupied. 
 
All cytometry measurements were carried out on samples in triplicate, gated on live 
cells and with 10,000 cells per sample. Data was analysed using FlowJo v10 and the 
median fluorescence intensity (MFI) for the fluorophore channel was plotted using 
Prism. 
 




CellTiter Glo 2.0 (Promega): KB cells (2 x104 cells/well) were cultured in 
supplemented FF-RPMI medium in a clear bottom 96 well-plate and incubated for 24 
h at 37 oC. 50, 100 and 500 nM concentrations of probes 1, 3, 5, 7 (in triplicate), or an 
untreated group, were incubated for 2 h at 37 oC. Plates were washed with PBS and 
fresh medium was added. CellTiter-Glo 2.0 reagent was added according to 
manufacturers instructions and the plate was shaken for 2 minutes. The solution was 
transferred to an opaque 96 well-plate and allowed to stand for 10 minutes at room 
temperature. Luminescence was measured using a Biotek Synergy HT microplate 
reader. Cell viability was reported as the mean percentage relative to untreated cells. 
 
NR8383 rat macrophages cell culture 
NR8383 rat alveolar macrophage cells were cultured in Ham’s F12K medium 
(Kaighns’ modification) supplemented with 15% heat inactivated fetal bovine serum 
(FBS) and penicillin/streptomycin. Cells were cultured at 37 oC in a 5% CO2 
atmosphere in a HeraCell incubator. Cells were subcultured twice per week by removal 
of suspension cells and resuspending these in fresh growth medium.  
 
NR8383 FR-β expression - flow cytometry 
NR8383 cells were plated in a flat-bottomed 24 well-plate (2.5 x105 cells/well). A 
subset of cells were stimulated with 10 ng/mL LPS + 10 ng/mL IFN-γ diluted in culture 
media, while the remainder were left untreated. Both groups were incubated for 24h at 
37 oC. Cells were transferred to FACS tubes and resuspended in FACS buffer (PBS + 
0.5% BSA). Fc mediated non-specific binding was blocked by incubating samples 




(1:10, 1:20, 1:50 dilutions) or an isotype control (clone MOPC-21) was added and 
samples incubated on ice for 30 minutes. After washing with FACS buffer, 7-AAD (5 
µL/test) was added according to manufacturer’s instructions. Samples were analysed 
by FACSCanto and the data processed with FlowJo. Cells were gated based on viable 
single cells with FSC/SSC distribution used to remove debris and with negative 7-
AAD staining (viable cells). Data was quantified using the geometric mean 
fluorescence intensity (MFI) of the channel of interest.  
 
NR8383 FR-β expression - Western blot 
Cell lysate was prepared from ~107 NR8383 and A549 cells. Cells were washed twice 
with PBS and lysed with freshly prepared RIPA buffer + 1X EDTA-free proteinase 
inhibitor cocktail (500 µl) for 30 min on ice. After lysis, insoluble material was 
pelleted by centrifugation at 13,000 g, 15 min at 4 oC. The supernatant was removed 
and the total protein content of lysate measured by the colorimetric DC assay (Biorad). 
2 µg/mL aliquots of cell lysate were prepared for Western blot.  
Western blotting was carried out using the ProteinSimple WES instrument following 
the manufacturer’s instructions and with the following antibodies; rabbit polyclonal 
FR-β antibody (dilutions of 1:50, 1:100, 1:200, 1:400) and HRP-labelled goat anti-
rabbit IgG secondary antibody (ProteinSimple).  
 
NR8383 confocal microscopy 
NR8383 cells (1.0 x 105 cells/ mL) were plated in ibidi 35mm µ-dish with high walls 




(250 nM) in fresh FF-RPMI and incubated for 30 min at 37 oC. Hoechst 33258 (1 
µg/mL) was added for the last 10 minutes of incubation. Confocal imaging was carried 
out on the Yokogawa CQ1 microscope located in GSK Stevenage. 
 
NR8383 flow cytometry 
NR8383 cells were prepared as in the receptor expression experiment and transferred 
to FACS tubes. Cells were washed with acidic sodium acetate saline solution (pH 4.5) 
for 1 min to remove surface bound folates.60 Probe 7 was added at 0 – 2.5 µM 
concentrations and incubated for 30 minutes at 37 oC. Competitive binding was 
assessed by incubating probe in the presence of 100 µM folic acid (FA). After 
incubation, the probe solution was removed, cells were washed with FACS buffer and 
7-AAD (5 µL/test) was added according to manufacturer’s instructions. Samples were 
analysed and the data processed with FlowJo. Cells were gated based on viable single 
cells with FSC/SSC distribution used to remove debris and negative 7-AAD staining. 
Data was quantified using the geometric mean fluorescence intensity (MFI) of the 
channel of interest. 
 
Human monocyte derived macrophages 
Human monocytes from healthy volunteers were collected by purification of 
peripheral blood mononuclear cells using CD14 positive magnetic bead separation 
(Miltenyi) according to manufacturer’s instructions. Monocyte-derived macrophages 
were differentiated with GM-CSF (50 ng/mL) for M1, or M-CSF (100 ng/mL) for M2 





Labelling of MDMs – flow cytometry 
M-CSF macrophages were plated in round bottom 96-well plates (1 x 106 cells/mL, 
100 μL/well) and cultured for 7 days to allow differentiation. Media was removed and 
cells incubated with a range of concentrations of Cy5**-Folate 7 (0, 10, 50, 100 and 
500 nM) for 30 min at 37oC. Competition was performed in the presence of 100-fold 
molar excess folic acid. After the incubation period the cells were rinsed with PBS 
once. Cells were transferred to FACS tubes and resuspended in FACS buffer (PBS + 
0.5% BSA). 7-AAD (5 μL/test) was added to each sample and put on ice for 5 minutes. 
Samples were then analysed and the data processed with FlowJo. Cells were gated for 
viable single cells using FSC/SSC distribution used to remove debris and negative 
7-AAD staining to remove dead cells. Data was quantified using the geometric mean 
fluorescence intensity (MFI) of the channel of interest.  
 
Labelling of MDMs – confocal microscopy 
GM-CSF or M-CSF macrophages were plated in ibidi μ-slide 8 well chamber slides (5 
x 104 cells/ mL, 300 μL/well) and cultured for 7 days to allow differentiation. Media 
was removed, cells were rinsed with PBS then incubated with Cy5**-Folate (250 nM) 
in FF-RPMI media (in the presence of 100-fold molar excess folic acid for competition 
assays) for 30 min at 37oC. Hoechst 33342 (1 μg/mL) and Calcein AM (0.5 μM) were 
added directly to the staining solution as counterstains for the last 10 min. After 
incubation the cells were rinsed with warm PBS once and fresh RPMI medium was 
added. Confocal imaging was carried out with a Leica SP5 microscope (settings: 
resolution 1024x1024 pixels; x63 oil objective; laser lines 405 nm, 488 nm, 633 nm; 




Images were extracted using the Leica LAS AF software and analysed with the Fiji 
distribution of ImageJ.140 
 
Labelling of M-CSF derived MDMs after stimulation – high content imaging 
MDMs were plated in black flat-bottom 96-well plates (1 x 106 cells/mL, 100 μL/well) 
and differentiated over 7 days with M-CSF (100 ng/mL). Three conditions were setup; 
untreated cells, cells that were stimulated with LPS (100 ng/mL) or stimulated with 
IL-4 (20 ng/mL) for 24 hours. The next day the media was removed and triplicate wells 
incubated with fresh FF-RPMI containing Cy5**-Folate (100 nM) or FolateSense (25 
nmol) for 30 min at 37 oC. Hoechst 33342 (1 μg/mL) was added as a counterstain for 
the final 10 minutes of incubation. The cells were washed with PBS once (300 μL) and 
then fresh FF-RPMI medium (100 μL) was added. Imaging was carried out on the 
CellInsight imaging system (ThermoFisher) and the mean fluorescence per object ± 
standard deviation was obtained. The data was processed in Prism. 
 
Timelapse imaging of Cy5**-Folate labelling – confocal microscopy 
MDMs that had been differentiated over 7 days with M-CSF (100 ng/mL) were plated 
in ibidi 35mm µ-dish with high walls (1.0 x 105 cells/ mL, 2 mL/well). After 7 days 
the media was removed and replaced with Cy5**-Folate (250 nM) in fresh FF-RPMI 
at 37 oC. Confocal imaging was carried out on the Yokogawa CQ1 microscope over 
15 hours, imaging every 15 minutes over multiple imaging fields. The fluorescence 






Labelling of primary BAL macrophages – flow cytometry 
Macrophages from BAL fluid were plated in round bottom 96-well plates (1 x 106 
cells/mL, 100 μL/well) and allowed to attach overnight. Media was removed and cells 
incubated with Cy5**-Folate (100 nM) for 30 min at 37 oC. After the incubation 
period the cells were rinsed with PBS once. Cells were transferred to FACS tubes and 
resuspended in FACS buffer (PBS + 0.5% BSA). Samples were then analysed and the 
data processed with FlowJo. Cells were gated for viable single cells using FSC/SSC 
distribution used to remove debris. Data was quantified using the geometric mean 
fluorescence intensity (MFI) of the Cy5 channel.  
 
Labelling of murine peritoneal macrophages 
Peritoneal macrophages were plated in ibidi μ-slide 8 well chamber slides (1 x 106 
cells/ well, 300 μL/well) and allowed to adhere overnight before the media was 
replaced on the next day. The cells were rinsed with PBS then incubated with Cy5**-
Folate (250 nM) in FF-RPMI media (competition experiments + 2.5 µM folic acid) 
for 30 min at 37 oC. Hoechst 33342 (1 μg/mL) was added as counterstain for the last 
10 min. The cells were rinsed with PBS once and fresh RPMI medium added (300 μL). 
Confocal imaging was performed with a Leica SP5 microscope (settings: resolution 
1024x1024 pixels; x63 oil objective; laser lines 405 nm, 633 nm; detection at 435-460 
nm (for Hoechst), 640-750 (for Cy5). 





These experiments were performed under Home Office License in compliance with 
the Animals (Scientific Procedures) Act 1986 and approved by the University of 





6.4. Chapter 3 
This experimental results of this chapter are a collaboration between myself, 
Edinburgh Molecular Imaging, Tom Speight (CIR) and Vrije Universiteit Brussels. 
The anti-MMR nanobody was provided by Vrije Universiteit Brussels, the protein 
conjugation was carried out by myself and Christophe Portal (Edinburgh Molecular 
Imaging). Characterisation and SDS-PAGE  of the labelled nanobody was carried out 




The following reagents and materials were purchased; Lysozyme from chicken egg 
white (Sigma, L4919), GE Illustra Nap-5 column (GE Healthcare, 17-0853-01), 
Amicon Ultra 0.5 mL 10k MWCO centrifugal filter membranes (Merck, UFC501024), 
Sephadex G-25 PD-10 column (GE Healthcare, 17085101) and PLRP-S 300Å HPLC 
column (Agilent, 5 μm, 250 x 4 mm). 
 
Validation of lysine labelling conditions - Cy5** labelled lysozyme 
O-(N-Succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TSTU, 2.64 mg, 
8.8 µmol, 1 equiv.) and N,N-dimethylaminopyridine (DIPEA, 1.2 µL, 12.3 µmol, 1.4 
equiv.) were added to N-methyl pyrolidinone (NMP, 50 µL). After one minute, 
Cy5.0** (7.8 mg, 8.8 µmol, 1 equiv.) in NMP (50 µL) was added. The reaction was 
monitored by HPLC (C18 5PCTMIN) and maximum conversion was reached after 1 





Lysozyme (4.19 mg, 0.033 equiv.) was dissolved in PBS (1 mL). Borate buffer (0.1 
M) was prepared by dissolving sodium borate (0.5 mg) in water and was added to the 
Lysozyme solution (200 µL). The Cy5**-NHS solution (33 µL) was added to the 
Lysozyme solution and shaken on an orbital shaker. The reaction was monitored by 
HPLC (C4 1PCTMIN) and shown to be 90% complete after 30 min. Half of the 
reaction mixture was quenched by adding hydroxylamine (5 equiv, 1.5 mg) to the 
mixture and shaken for 15 min. The crude reaction mixture was purified using a Nap-
5 column and eluting with PBS. 
 
Labelling of MMR nanobody 
The anti-MMR nanobody clone 3.49 (MMR 3.49, provided by Vrije Universiteit 
Brussels) was provided without a His tag tail. Fluorophore labelling was carried out 
by a random lysine labelling procedure with a 5-molar excess of reactive dye. Briefly, 
dye NHS-ester activation was performed by dissolving SulfoCy5 (1.0 mg, 1.50 µmol) 
in anhydrous N-N-dimethylformamide (DMF, 80 µL) and N,N-diisopropylethylamine 
(0.4 µL, 2.3 µmol) was added. O-(N-Succinimidyl)-1,1,3,3-tetramethyluronium 
tetrafluoroborate (0.46 mg, 1.50 µmol) in DMF (40 µL) was subsequently added and 
the reaction mixture stirred for 1 hour. Upon complete conversion to the active ester 
(SulfoCy5-NHS), the nanobody (3.8 mg, 0.3 µmol) in PBS (1 mL, 0.1 M) was added 
and the mixture incubated for 3 hours. The labelled nanobody was purified by PD-10 
gel or centrifugation (15,000 x g, 10k MWCO Amicon centrifugal filters) using PBS 
(pH 7.4) as buffer. 
 




Fluorophore conjugation was confirmed by RP-HPLC and mass spectrometry. The 
nanobody was characterised by HPLC (Agilent 1100 series, PLRP-S 300Å, 5 µm, 
250x4 mm). The following gradient was used 25% H2O in acetonitrile for 5 minutes, 
increase to 34% H2O in 2 minutes, increase to 100% H2O over 3 minutes, isocratic 
elution at 100% H2O for 15 minutes. All solvents had 0.1% TFA as additive. Detection 
at 280 nm and 647 nm was used for analysis of protein and dye, respectively, as well 
as fluorescence detection (λEx 647, λEm 670 nm). 
 
Mass spectrometry was performed using IMS-MS (Waters Synapt Q-ToF, direct 
infusion). The IMS data was processed and analysed using MassLynx (Waters). 
 
Nanobody characterisation – spectroscopy 
The concentration of labelled nanobody and degree of labelling (DOL) was determined 
by UV/Vis absorbance. UV/Vis absorbance measurements were made on a Nanodrop 
1000 spectrometer, measuring the absorbance of the dye and labelled protein at A280 
and Amax.  
 
𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑀) =  
[𝐴280 − (𝐴𝑚𝑎𝑥  ×  𝐶𝐹)]  × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
𝜀
 
CF correction factor for the dye, adjusting for dye absorbance at 280 nm 
ε is molar extinction coefficient of the protein 
 
𝑑𝑒𝑔𝑟𝑒𝑒 𝑜𝑓 𝑙𝑎𝑏𝑒𝑙𝑙𝑖𝑛𝑔 (𝑑𝑦𝑒 𝑝𝑒𝑟 𝑝𝑟𝑜𝑡𝑒𝑖𝑛) =  
𝐴𝑚𝑎𝑥 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
𝜀′ × 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐. (𝑀)
 





Fluorescence spectra were recorded in polystyrene cuvettes using a FluoroMax 
spectrofluorometer with solutions having an absorbance less than 0.1 a.u. to avoid 
inner-filter effects. 
 
6.4.2. Biological studies 
Materials 
The following reagents and materials were purchased; anti-human PE-CD206 
antibody (Biolegend 321105), Precision Plus Protein Kaleidoscope™ Standards 
(BioRad 161-0375), 4X Laemelli sample buffer (BioRad 161-0747), Colloidal 




The protein samples (0.5 μg unlabelled MMR, and 0.5 and 1 μg Cy5-Nb) were reduced 
in Laemelli sample buffer at 90 °C for 5 minutes. The reduced sample was loaded onto 
a handcast SDS-tricine gel (10% separating and 3% stacking gel). SDS-tricine PAGE 
was performed under reducing conditions according to a published protocol.141 The 
Precision Plus Kaleidoscope™ protein ladder was used as a molecular weight 
standard. Visualisation of protein bands was performed using the colloidal Coomassie 
staining kit (BioRad) according to the manufacturer’s instructions and imaged with the 














XD-OH was prepared by according to a previously reported procedure.124 Resorcinol 
(82 mg, 0.76 mmol), K2CO3 (104 mg, 0.76 mmol) were dissolved in MeCN (10 mL) 
and stirred to room temperature for 15 min. To this a solution of IR780 iodide (200 
mg, 0.30 mmol) in MeCN (2.5 mL) was added and the reaction mixture heated to 50 
oC for 6 h. Conversion was observed by TLC (DCM:MeOH 98:2) and the reaction 
mixture was concentrated, then separated between DCM/ water. The organics were 
extracted with DCM and washed with 0.1 M HCl solution, brine and dried over 
MgSO4. The product was obtained in sufficient purity as a blue solid (176 mg, 100 %). 
Data in agreement with the literature.124 HPLC (Method 1) tR = 4.5 min, Purity = 90 % 
(ELSD). MS (ESI): calculated for C28H30NO2 [M]
+ m/z 412.2. Found 412.3 (100%). 
1H NMR (500 MHz, Chloroform-d) δ 8.42 (d, J = 13.9 Hz, 1H), 7.40 (dd, J = 7.5, 1.2 
Hz, 1H), 7.35 (d, J = 7.3 Hz, 2H), 7.25 – 7.19 (m, 2H), 7.13 (s, 1H), 7.04 (dd, J = 14.6, 
8.6 Hz, 2H), 5.91 (d, J = 14.0 Hz, 1H), 3.96 (t, J = 7.5 Hz, 2H), 2.73 (t, J = 6.2 Hz, 
2H), 2.63 (t, J = 6.4 Hz, 2H), 1.91 (tt, J = 14.9, 7.0 Hz, 4H), 1.74 (s, 6H), 1.08 (t, J = 




139.2, 129.3, 128.6, 124.9, 122.7, 115.4, 115.1, 110.0, 103.5, 98.0, 49.3, 45.8, 28.8, 




XD-BGal was prepared by according to a previously reported procedure.124 XD-OH 
(100 mg, 0.19 mmol), Na2SO4 (65 mg, 0.46 mmol) and Cs2CO3 (155 mg, 0.46 mmol) 
were dissolved in MeCN (10 mL) and stirred at room temperature under N2 for 15 
mins. α-bromo galactose tetraacetate (124 mg, 0.38 mmol) was added and the reaction 
stirred for 48 hr. The solvent was evaporated under vacuum and the residue purified 
by flash column chromatography (DCM:MeOH 0% to 10%) to obtain a blue solid. The 
acetylated galactose was deprotected with a solution of K2CO3 (6.5 mg) in MeOH (1 
mL) and stirred for 1 h. HPLC confirmed the complete deprotection of the starting 
material and the compound was purified by flash column chromatography 
(DCM:MeOH 0% to 20%) to give a blue solid (30 mg, 30 % over two steps). Data in 
agreement with the literature.124 Rf = 0.39 (10% MeOH:DCM). HPLC (Method 1) tR 
= 3.8 min, Purity = 100 % (ELSD). HRMS (ESI) m/z: [M]+ Calcd for C34H40NO7 
574.2799. Found 574.2755. 1H NMR (500 MHz, DMSO-d6) δ 8.61 (d, J = 15.0 Hz, 




7.17 (d, J = 4.8 Hz, 2H), 6.65 (d, J = 15.1 Hz, 1H), 5.04 – 4.97 (m, 1H), 4.33 – 4.27 
(m, 2H), 4.20 – 4.13 (m, 1H), 3.99 – 3.93 (m, 2H), 3.92 – 3.79 (m, 3H), 2.72 (d, J = 
6.8 Hz, 2H), 2.68 (t, J = 6.2 Hz, 2H), 1.92 – 1.82 (m, 4H), 1.79 – 1.75 (m, 6H), 0.99 
(t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 178.3, 159.6, 158.4, 145.2, 142.3, 
141.4, 131.7, 128.9, 128.1, 127.4, 122.7, 117.0, 114.1, 113.4, 106.1, 105.4, 103.9, 96.9, 




XD-Br was prepared by according to a previously reported procedure.124 4-
bromoresorcinol (144 mg, 0.76 mmol), K2CO3 (104 mg, 0.76 mmol) were dissolved 
in MeCN (2.5 mL) and stirred to room temperature for 15 min. To this a solution of 
IR780 iodide (200 mg, 0.30 mmol) in MeCN (2.5 mL) was added and the reaction 
mixture heated to 50 oC for 6 h. Conversion was observed by TLC (DCM:MeOH 98:2) 
and upon completion the reaction mixture was concentrated and diluted with DCM/ 
water. The organics were extracted with DCM, washed with 0.1 M HCl solution, then 
brine and dried over MgSO4. The product was concentrated under vacuum to obtain a 
blue solid (69 mg, 37 %). Data in agreement with the literature.124 HPLC (Method 1) 
tR = 4.7 min, Purity = 100 % (ELSD). ESI-MS: calculated for C28H30NO2 [M]
+ m/z 




Hz, 1H), 7.58 (s, 1H), 7.34 – 7.27 (m, 2H), (1H obscured by CDCl3), 7.11 (td, J = 7.4, 
0.9 Hz, 1H), 6.90 (d, J = 7.9 Hz, 1H), 6.76 (s, 1H), 5.72 (d, J = 13.7 Hz, 1H), 3.83 (t, 
J = 7.4 Hz, 2H), 2.67 (t, J = 6.1 Hz, 2H), 2.59 (t, J = 6.2 Hz, 2H), 1.92 – 1.77 (m, 4H), 
1.64 (s, 6H), 1.03 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 161.1, 157.7, 
153.3, 143.3, 140.2, 139.1, 132.2, 131.0, 128.4, 123.3, 122.4, 115.8, 109.8, 108.8, 




XD-Br (30 mg, 0.056 mmol) and Cs2CO3 (56 mg, 0.168 mmol) were dissolved in 
DCM (3 mL) and stirred at room temperature under N2 for 15 mins. α-bromo galactose 
tetraacetate (70 mg, 0.168 mmol) was added and the reaction stirred for 18 hr. The 
solvent was evaporated under vacuum and the residue purified by flash column 
chromatography (DCM:MeOH 0% to 8%) to obtain a blue solid (10 mg, 22%). Rf = 
0.55 (8% MeOH:DCM). HPLC (Method 1) tR = 4.8 min, Purity = 92 % (650 nm). MS 
(ESI): calculated for C42H47NO11Br [M]
+ m/z 820.2. Found 822.2 (100%). 
1H NMR (500 MHz, Chloroform-d) δ 8.78 (d, J = 15.1 Hz, 1H), 7.63 – 7.58 (m, 2H), 
7.54 – 7.46 (m, 2H), 7.43 (td, J = 7.5, 1.0 Hz, 1H), 7.38 (d, J = 7.9 Hz, 1H), 7.05 (s, 




5.29 – 5.26 (m, 1H), 4.71 – 4.65 (m, 1H), 4.59 (t, J = 7.5 Hz, 2H), 4.45 (dd, J = 10.9, 
5.7 Hz, 1H), 4.15 – 4.09 (m, 2H), 2.86 – 2.70 (m, 4H), 2.21 (s, 3H), 2.11 (d, J = 5.3 
Hz, 3H), 2.08 (d, J = 3.7 Hz, 3H), 2.03 (s, 3H), 2.01 (s, 3H), 1.90 (s, 3H), 1.86 (s, 3H), 




The acetylated protected compound XD-BrBGal protected (10 mg) was deprotected 
with a solution of K2CO3 (6.5 mg) in MeOH (1 mL) after stirring at rt for 1 h. HPLC 
confirms the complete deprotection of the starting material (tR = 3.9 min) and the 
compound was purified by RP-HPLC (system 1) to give a blue solid (6 mg, 71 %). Rf 
= 0.60 (8% MeOH:DCM). HPLC (Method 1) tR = 3.95 min, Purity = 87 % (650 nm). 
HRMS (ESI/Q-TOF) m/z: [M]+ Calcd for C34H39BrNO7 652.1904. Found 652.1904. 
1H NMR (500 MHz, D2O) δ 8.55 – 8.44 (br), 8.47 (d, J = 15.1 Hz, 1H), 7.65 (d, J = 
7.3 Hz, 1H), 7.58 – 7.47 (m, 4H), 7.03 (s, 1H), 6.98 (s, 1H), 6.44 (d, J = 15.1 Hz, 1H), 
5.04 (d, J = 7.7 Hz, 1H), 4.25 (t, J = 7.3 Hz, 2H), 4.12 (d, J = 3.4 Hz, 1H), 3.99 – 3.93 
(m, 2H), 3.92 – 3.79 (m, 3H), 2.72 – 2.59 (m, 2H), 2.56 (t, J = 5.7 Hz, 2H), 1.92 – 1.82 
(m, 4H), 1.77 (s, 3H), 1.67 (s, 3H), 0.97 (d, J = 7.6 Hz, 3H). 13C NMR (126 MHz, 




117.0, 114.1, 113.4, 106.1, 105.4, 103.9, 96.9, 70.5, 70.1, 69.8, 61.1, 50.7, 30.7, 28.5, 




Resorcinol (55 mg, 0.50 mmol), K2CO3 (70 mg, 0.50 mmol) were dissolved in DMF 
(2.5 mL) and stirred at room temperature for 15 min. To this a solution of IR783 iodide 
(150 mg, 0.20 mmol) in DMF (0.5 mL) was added and the reaction heated to 50oC for 
6 h. Conversion was observed by TLC (DCM:MeOH 90:10) and upon completion the 
reaction mixture was concentrated. The product was isolated by RP-flash 
chromatography (Biotage C18 Ultra 50g, 10% - 50% ACN in H2O, with 0.1% formic 
acid) and the product fractions were lyophilised to give a deep blue powder (70 mg, 
69 %). HPLC (Method 1) tR = 4.1 min, Purity = 100 % (ELSD). HRMS (ESI/Q-TOF) 
m/z: [M+H]+ Calcd for C29H31NO5S 506.1996. Found 506.2001. 
1H NMR (500 MHz, 
Methanol-d4) δ 8.54 (d, J = 14.5 Hz, 1H), 7.59 (s, 1H), 7.51 (d, J = 7.4 Hz, 1H), 7.44 
– 7.37 (m, 2H), 7.32 (d, J = 8.4 Hz, 1H), 7.24 (t, J = 7.5 Hz, 1H), 6.76 (dd, J = 8.8, 2.2 
Hz, 1H), 6.65 (s, 1H), 6.20 (d, J = 14.0 Hz, 1H), 4.56 (s, 2H), 4.16 (t, J = 7.2 Hz, 2H), 
2.90 (t, J = 7.1 Hz, 2H), 2.78 (t, J = 6.1 Hz, 2H), 2.74 (t, J = 6.2 Hz, 2H), 2.02 – 1.91 







SulfoXD-OH (20 mg, 0.04 mmol) and Cs2CO3 (40 mg, 0.12 mmol) were dissolved in 
DMF (2 mL) and stirred at room temperature under N2 for 15 mins. α-bromo galactose 
tetraacetate (50 mg, 0.12 mmol) was added and the reaction stirred for 48 hr at room 







Compound 20 was prepared according to a reported procedure.142 Silver oxide (464 
mg, 2.0 mmol) and 4-hydroxybenzaldehyde (134 mg, 1.1 mmol) were added to a 
solution of α-D-galactopyranosyl bromide (416 mg, 1.0 mmol) in acetonitrile (10 mL). 
The mixture was stirred at room temperature for 16h, filtered on celite and the pad 
washed with EtOAc. The filtrate was concentrated under vacuum and purified by flash 
column chromatography (1:1 to 7:3 EtOAc-Hexane) to give an oil which was 
thoroughly dried under high vacuum, giving a white powder (370 mg, 82%). Data in 
agreement with the literature.142 Rf = 0.62 (EtOAc/hexane 7:3). HPLC (Method 1) tR 
= 4.7 min, Purity = 100 % (ELSD). ESI-MS: calculated for C21H24O11 [M+Na]
+ m/z 
475.1. Found 475.1 (100%). 1H NMR (500 MHz, Chloroform-d) δ 9.93 (s, 1H, CHO), 
7.86 (d, J = 8.8 Hz, 2H, CHAr), 7.11 (d, J = 8.7 Hz, 2H, CHAr), 5.52 (dd, J = 10.4, 7.9 
Hz, 1H), 5.48 (dd, J = 3.4, 1.1 Hz, 1H), 5.17 (d, J = 7.9 Hz, 1H), 5.14 (dd, J = 10.4, 
3.4 Hz, 1H), 4.26 – 4.09 (m, 3H), 2.19 (s, 3H), 2.07 (s, 3H), 2.07 (s, 3H), 2.02 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 190.8, 170.4, 170.3, 170.2, 169.4, 161.4, 132.0 (2C), 








Compound 21 was prepared according to a reported procedure.142 Sodium borohydride 
(17.5 mg, 0.46 mmol) was added portion-wise to a cooled solution of aldehyde (100 
mg, 0.21 mmol) in CHCl3-iPrOH (25 mL: 8 mL) at 0°C. The solution was allowed to 
reach room temperature and stirred for 3h. An aqueous solution of citric acid (10% 
(w/w), 25 mL) was added. The organics were extracted and washed with NaHCO3 
(10% (w/w), 3x 15 mL) and water (15mL), the organic phase was dried over MgSO4 
and filtered. The solvent was evaporated under vacuum and the residue purified by 
flash column chromatography (EtOAc-hexane 1:1). The product fractions were dried 
under high vacuum to give a white solid (90 mg, 95 %). Data in agreement with the 
literature.142 Rf = 0.30 (EtOAc/hexane 1:1). HPLC (Method 1) tR = 4.2 min, Purity = 
100 % (ELSD). ESI-MS: calculated for C21H24O11 [M+Na]
+ m/z 477.1. Found 477.1 
(100%). 1H NMR (601 MHz, Chloroform-d) δ 7.31 (d, J = 8.6 Hz, 2H), 7.00 (d, J = 
8.6 Hz, 2H), 5.49 (dd, J = 10.5, 7.9 Hz, 1H), 5.46 (dd, J = 3.5, 1.1 Hz, 1H), 5.11 (dd, 
J = 10.5, 3.5 Hz, 1H), 5.03 (d, J = 8.0 Hz, 1H), 4.65 (d, J = 5.7 Hz, 2H), 4.23 (dd, J = 
11.4, 6.9 Hz, 1H), 4.16 (dd, J = 11.4, 6.4 Hz, 1H), 4.06 (td, J = 6.7, 1.2 Hz, 1H), 2.19 
(s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 2.02 (s, 3H). DEPT-135 13C NMR (151 MHz, 




20.73, 20.67, 20.59. 13C NMR (126 MHz, Chloroform-d) δ 170.5, 170.4, 170.3, 169.5, 





Gal-Bn-PNP was prepared according to a reported procedure.142 4-nitrophenyl 
chloroformate (120 mg, 0.6 mmol) was added at room temperature to a mixture of the 
alcohol (90 mg, 0.2 mmol) and pyridine (48 μL, 0.6 mmol) in EtOAc (3 mL). The 
mixture was stirred for 20h at room temperature and diluted with DCM (20 mL). After 
washing with NaHCO3 solution (5%w/w, 20 mL) and water (20 mL) the organic phase 
was dried over MgSO4. The solvent was evaporated under vacuum and the residue 
purified by flash column chromatography (EtOAc-hexane 15:5 then 5:5) to give a 
yellow oil (60 mg, 48%). Data in agreement with the literature.142 Rf = 0.53 (3:1 
EtOAc:Hexane). HPLC (Method 1) tR = 5.2 min, Purity = 100 % (ELSD). ESI-MS: 
calculated for C28H29NO15 [M+Na]
+ m/z 642.1. Found 642.1 (100%). 1H NMR (500 
MHz, Chloroform-d) δ 8.30 – 8.24 (m, 2H), 7.40 (d, J = 8.6 Hz, 2H), 7.38 – 7.34 (m, 
2H), 7.07 – 7.00 (m, 2H), 5.50 (dd, J = 10.5, 7.9 Hz, 1H), 5.46 (dd, J = 3.4, 1.1 Hz, 
1H), 5.25 (s, 2H), 5.12 (dd, J = 10.5, 3.4 Hz, 1H), 5.07 (d, J = 7.9 Hz, 1H), 4.27 – 4.13 




3H). 13C NMR (126 MHz, Chloroform-d) δ 170.5, 170.3, 170.3, 169.5, 157.6, 155.6, 
152.6, 145.6, 130.7, 129.2, 125.5, 121.9, 117.2, 99.6, 71.3, 70.9, 70.6, 68.7, 67.0, 61.5, 




Benzyl-Cy7 was prepared according to a reported procedure.143 IR780 (50 mg, 93 
µmol) and benzylamine (33 µL, 4 eq.) were dissolved in acetonitrile in an oven dried 
flask and filled with a nitrogen atmosphere. DIPEA (26 µL, 2 eq.) was added and the 
reaction heated to 80 C with monitoring by TLC. The reaction mixture was 
neutralised with 0.1 M HCl, diluted in DCM and dried over MgSO4. The organics were 
concentrated under vacuum to give a dark metallic coloured solid (140 mg, 100 %). 
Data in agreement with the literature.143 Rf = 0.38 (8% MeOH in DCM). ESI-MS: 
calculated for C43H52N3
+ [M+H]+ m/z 610.4. Found 610.4 (100%). HPLC (Method 1) 
tR = 5.6 min, Purity 95% (ELSD). 
1H NMR (500 MHz, Chloroform-d) δ 7.67 (d, J = 
12.9 Hz, 2H), 7.46 – 7.30 (m, 5H), 7.24 – 7.19 (m, 4H), 7.03 (t, J = 7.5 Hz, 2H), 6.82 
(d, J = 7.9 Hz, 2H), 5.60 (d, J = 12.9 Hz, 2H), 5.11 – 5.03 (m, 2H), 3.82 – 3.70 (m, 
4H), 2.48 (t, J = 6.3 Hz, 4H), 1.90 – 1.74 (m, 6H), 1.48 (s, 12H), 1.01 (t, J = 7.5 Hz, 
6H). 13C NMR (126 MHz, Chloroform-d) δ 170.1, 143.5, 142.8, 140.6, 137.0, 129.3, 




HSQC: 1H-13C NMR ((500, 126) MHz, Chloroform-d) δ (7.7 139.6), (7.5 128.6), (7.4 
129.7), (7.3 128.8), (7.3 128.7), (7.2 122.7), (7.1 123.4), (6.9 109.0), (5.6 95.3), (5.1 
53.5), (4.9 53.6), (3.8 45.4), (2.5 26.0), (1.9 22.1), (1.8 20.7), (1.5 29.3), (1.0 12.3). 
 
6.5.2. Singlet oxygen generation assay  
The SOSG assay was adapted from the reported procedure by Lin.134 Concentrations 
of fluorescent dyes (5 μM) and SOSG (5 μM) in aerated methanol solutions were 
irritated for 30 minutes with a distance of 16 cm. Irradiation was performed using a 
white LED lamp (ThorLabs) with 610 nm LP filter (power density 1.2 mW cm-2). The 
fluorescence emission (Ex = 488 nm, Em = 520 nm) was measured (Synergy HT) 
allowing the singlet oxygen quantum yield to be determined by the comparative 
method. 
 
6.5.3. Biological studies 
Materials 
The following reagents and materials were purchased; HBSS (Gibco 14025-050),  
Senescence detection kit (Abcam ab65351), β-galactosidase from E. coli (Sigma 
G4155), bleomycin sulphate (Apollo Scientific, BI3543), Prolong Gold (Invitrogen, 
P36934). 
 
HPLC analysis of XD-BGal activation  
XD-BGal (100 µM) in PBS+5% DMSO was incubated with recombinant β-




to remove protein and analysed by RP-HPLC. Analysis was performed with HPLC 
(method 1) monitoring absorbance at 650 nm. 
 
Kinetic analysis of the probe with β-Galactosidase 
XD-BGal (100 µM) in PBS+5% DMSO, added to a 96-well plate and incubated with 
concentrations of recombinant β-galactosidase (0, 5, 10, 25 nM) at 37°C. The 
fluorescence was measured by plate reader with 633 nm excitation after 0, 10- and 30-
minute time points. To calculate the kinetic parameters, 1-20 µM XD-BGal was 
incubated with 5 nM β-Gal at 37°C for 30 minutes. The fluorescence was measured 
over time.  
 
Inducing cellular senescence in A549 cells 
A549 cells were cultured 6-well plates in complete DMEM until 60% confluent. Cells 
were then treated with PBS (750 μL) containing bleomycin sulphate (50 μg/mL) for 2 
hours. Cells were gently washed 2 times in warm PBS and cultured for 7 days in 
complete DMEM media. Cells were observed for a change in morphology under a 
microscope. 
 
X-gal staining – fluorescence microscopy 
X-gal staining was carried out according to the protocol of the Abcam senescence 
detection kit. Briefly, senescent A549 cells (groups: untreated and bleomycin treated) 
were washed twice in warm PBS and incubated in fixative solution for 10 mins at room 




at pH 6.0 at 37 °C (without CO2). Cells were then bright field imaged for colour 
development on the Z1 profiler microscope (Charles Zeiss). Positively stained cells 
were counted using Image-J cell counter plugin. 
 
Imaging galactosidase activity – confocal microscopy 
Acid-washed coverslips were placed in the bottom of a 6-well plate and treated with 
0.1 mg/mL poly-D-lysine solution for 5 mins at room temperature, then washed twice 
in PBS. A549 cells (4 x 104 cells/mL) were cultured on coverslips in complete DMEM 
until 60% confluent. Cells were treated with 50 μg/mL bleomycin sulphate (750 μL 
PBS) for 12 hours. Cells were gently washed 2X in warm PBS and cultured for 5 days 
in complete DMEM media. Proliferating cells were seeded on the lower row of wells 
containing coverslips and cultured overnight until ~80% confluent. Cells were then 
washed three-times in warm PBS before 1 hour incubation in serum-free DMEM 
containing 10 μM XD-BGal and 0.1 μg/mL Hoechst. Cells were washed in warm PBS 
(2X) and mounted in Prolong Gold aqueous mountant and imaged on a Leica SP8 
confocal microscope (laser lines: 405 nm (Hoechst) and 633nm (XD-BGal). Images 
were extracted using the Leica LAS AF software and analysed with the Fiji distribution 
of ImageJ.140 
 
Lung tissue slices were prepared by Philip Emmanuel and confocal microscopy was 
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8.1. Video files (on CD) 
8.1.1. Figure 2.38: Timelapse video showing the uptake of Cy5**-Folate by M2 
MDMs  
8.1.2. Figure 3.17: 3D visualisation of macrophage labelling with Cy5**-Nb 
generated using spinning disk microscopy and analysed in Imaris. 
8.1.3. Figure 3.18: Timelapse imaging of MDMs labelled with with Cy5**-Nb 
generated with spinning disk microscopy 
 
 
